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Cutaneous leishmaniasis is a chronic disease characterized by ulcerating and disfiguring skin lesions.
Infection with different species of Leishmania parasites is responsible for the initiation of this disease, yet
most of the pathology observed is mediated by an unregulated immune response. The work presented in
this thesis investigated the roles of IL-22 and the skin microbiota in regulating immune mediated
pathology during cutaneous leishmaniasis. We found that IL-22, a cytokine important in wound repair in
the skin, was required to limit pathology when mice were infected with L. major. In order to promote lesion
resolution, IL-22 induced keratinocyte migration and decreased IL-1α and IL-1β production, both
important stages in tissue repair. Interestingly, this protective role for IL-22 was only observed with a high
dose of infection, suggesting a threshold of inflammation is required for IL-22 to limit pathology. We also
found that the L. major infection in mice, as well as, L. braziliensis infection in humans caused a dysbiosis
in the skin microbiota on lesional skin and nearby skin sites, characterized by a dominance of
Staphylococcus spp. or Streptococcus spp. Interestingly, this dysbiotic microbiota was also transmissible
to co-housed na�ve skin and exacerbated skin inflammation during L. major infection and during an
acute contact hypersensitivity model. These data are the first to demonstrate that a dysbiotic skin
microbiota can be transmitted to non-inflamed tissue and demonstrate how a naturally occurring
dysbiosis can worsen disease during cutaneous leishmaniasis. Work presented in this thesis
demonstrates that both IL-22 and the skin microbiota have distinct roles during cutaneous leishmaniasis.
Future studies will be aimed at how these factors can be regulated to aid in the treatment of the disease.
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ABSTRACT
REGULATING IMMUNE MEDIATED PATHOLOGY IN CUTANEOUS
LEISHMANIASIS: ROLES FOR IL-22 AND SKIN MICROBIOTA
Ciara Gimblet
Phillip Scott, Ph.D.

Cutaneous leishmaniasis is a chronic disease characterized by ulcerating
and disfiguring skin lesions. Infection with different species of Leishmania
parasites is responsible for the initiation of this disease, yet most of the pathology
observed is mediated by an unregulated immune response. The work presented
in this thesis investigated the roles of IL-22 and the skin microbiota in regulating
immune mediated pathology during cutaneous leishmaniasis. We found that IL22, a cytokine important in wound repair in the skin, was required to limit
pathology when mice were infected with L. major. In order to promote lesion
resolution, IL-22 induced keratinocyte migration and decreased IL-1α and IL-1β
production, both important stages in tissue repair. Interestingly, this protective
role for IL-22 was only observed with a high dose of infection, suggesting a
threshold of inflammation is required for IL-22 to limit pathology. We also found
that the L. major infection in mice, as well as, L. braziliensis infection in humans
caused a dysbiosis in the skin microbiota on lesional skin and nearby skin sites,
characterized by a dominance of Staphylococcus spp. or Streptococcus spp.
Interestingly, this dysbiotic microbiota was also transmissible to co-housed naïve
skin and exacerbated skin inflammation during L. major infection and during an
vi

acute contact hypersensitivity model. These data are the first to demonstrate that
a dysbiotic skin microbiota can be transmitted to non-inflamed tissue and
demonstrate how a naturally occurring dysbiosis can worsen disease during
cutaneous leishmaniasis. Work presented in this thesis demonstrates that both
IL-22 and the skin microbiota have distinct roles during cutaneous leishmaniasis.
Future studies will be aimed at how these factors can be regulated to aid in the
treatment of the disease.
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CHAPTER 1: INTRODUCTION

1.1 Leishmaniasis
Leishmaniases are a group of diseases caused by infection with
protozoan parasites belonging to the genus, Leishmania spp. Affecting people in
over 90 countries worldwide, leishmaniasis has had a major impact on human
health. Yet, it still remains a neglected tropical disease (CDC 2013). There are
over 20 species of the parasite that cause disease in humans and about 30
species of phlebotomine sand flies that carry the parasite. In the sand fly,
leishmania parasites mature into metacyclic promastigotes, which are injected
into the skin of the mammalian hosts during blood feeding. Once injected into the
skin, the promastigotes are taken up by phagocytic cells, where they transform
into the replicative amastigote stage. After multiple rounds of replication, these
amastigotes burst from the cell and then can infect other phagocytic cells. The
infected phagocytes are then taken up upon blood feeding by another sand fly,
where the parasites differentiate into the promastigote stage, completing the life
cycle (Kaye and Scott 2011).
Depending on the species, the disease can manifest in several forms:
visceral, cutaneous, diffuse cutaneous and mucocutaneous. Visceral
leishmaniasis, caused mostly by Leishmania donovani and Leishmania infantum,
affects several internal organs causing fever, weight loss and anemia and
untreated cases of visceral leishmaniasis are almost always fatal. Cutaneous
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leishmaniasis is the most common form throughout the world and can manifest in
ulcerating lesions, many of which can resolve but leave disfiguring scars. The
predominant species that cause cutaneous leishmaniasis are the Old World
species, Leishmania major, and the New World species Leishmania mexicana,
Leishmania amazonensis, Leishmania braziliensis, Leishmania panamanensis.
Some individuals infected with L. braziliensis and L. panamanensis develop
chronic ulcers that have the potential to progress to the mucocutaneous form,
which can cause severe disfiguration (Kedzierski 2011).
Leishmania parasites can infect a variety of mammalian hosts, including
humans, dogs, and rodents. In certain countries where leishmaniasis is endemic,
infected domestic dogs are considered the predominant reservoir for leishmania
parasites and have been targeted to help prevent the spread of the disease
(Oliveira et al. 2008; Lima et al. 2012; Esch et al. 2012). Control of the sand fly
vector has also been tested as a measure to help prevent new infections, but it is
not yet clear whether it will be useful for all forms of the disease (Gonzalez et al.
2015). The development of an effective vaccine would provide an additional
measure of disease control and is an area of active investigation.
Pentavalent antimonial therapies have been the first line of treatment for
patients with leishmaniasis for almost 70 years. However many patients require
multiple rounds of treatment before a successful cure is reached, and can
experience severe side effects due to drug toxicity (Kedzierski 2011). Currently,
there is no protective vaccine against human leishmaniasis despite many
2

experimental efforts and large human trials over the past 25 years (Basu et al.
2005; Chakravarty et al. 2011; Bhattacharya et al. 2015; Miura et al. 2015)Most
vaccine strategies have been focused on developing strong antibody responses,
yet prior studies have shown that antibodies have no protective effect on the
disease (Glennie and Scott 2016). The success of future vaccine strategies
depends on a thorough understanding of how protective immunity is achieved.

1.2 Protective immune responses in leishmaniasis
Leishmania parasites also infect and cause disease in mice, making the
murine model of infection useful in studying the immune response. For
cutaneous leishmaniasis, L. major has been the most widely used parasite in
these studies. Seminal work using the mouse model demonstrated that
susceptibility to infection with leishmania parasites depends on the strain of
mouse (Kellina 1973). Subsequent studies focused on understanding the
immunological differences that lead to susceptibility and resistance to leishmania.
Several studies demonstrated that an IL-4 driven Th2 immune response was
responsible for uncontrolled parasite growth in susceptible mouse strains, while
the production of IFN-γ from activated Th1 cells were responsible for control of
parasite growth (Scott et al. 1988; Heinzel et al. 1989; Sadick et al. 1990; Heinzel
et al. 1993; Sypek et al. 1993; Kopf et al. 1996). IL-12 is the key cytokine that
initiates the protective Th1 response (Mattner et al. 1996; Scharton-Kersten et al.
1995). Upon infection with leishmania parasites, reactive oxygen species (ROS)
3

are induced in phagocytic cells. This response, known as the respiratory burst
can kill a portion of the parasites. However, a stronger anti-parasitic response
requires the release of IFN-γ, which induces infected cells to produce more ROS
and nitric oxide (NO) (Scott and Novais 2016). Interestingly, unlike in murine
macrophages, NO is not induced or required for parasite killing in human cells
which rely more on the respiratory burst (Novais et al. 2014b). This data
suggests that mice and humans eliminate the parasite using different
mechanisms. Nonetheless, it is clear that in both mice and humans, IFN-γ is
required to effectively control parasite growth.
There are several sources of IFN-γ during leishmania infections, including
CD4 T cells, CD8 T cells, γδ T cells, and NK cells. While CD4 T cells are the
most crucial source for parasite control (Chakkalath et al. 1995; Erb et al. 1996),
IFN-γ from CD8 T cells and NK cells is important in fortifying the protective Th1
response (Belkaid et al. 2002b; Scharton and Scott 1993; Uzonna, Joyce, Scott
2004; Laouar et al. 2005). In addition, TNF-α acts synergistically with IFN-γ to
enhance parasite killing (Bogdan et al. 1990; Green et al. 1990). These studies
demonstrate the need for multiple arms of the immune response working
together to effectively control parasite growth.
The innate response also plays a role in contributing to the protective Th1
immune response. Upon recognition of the parasite, NK cells are responsible for
the early IFN-γ production (Scharton and Scott 1993; Bajenoff et al. 2006). Even
cells from the non-hematopoietic niche contribute to initiating and maintaining a
4

protective Th1 response. Keratinocytes can be an early source of IL-12, as well
as other cytokines that promote IFN-γ production (Ehrchen et al. 2010).
Even in the face of a strong Th1 response, leishmania parasites persist
after the resolution of the lesion, leading to a concomitant immunity that protects
against reinfection. The mechanism of how the parasite persists is not completely
clear, but the production of the regulatory cytokine, IL-10, plays a role by
dampening the Th1 response (Belkaid et al. 2001; Belkaid et al. 2002a). It is
thought that protection against reinfection requires parasite persistence and that
this immunity is dependent upon both CD4 and CD8 memory T cells (Muller
1992). In cutaneous leishmaniasis, both short-lived effector memory T cells and
long-lived central memory T cells are required for protection against re-infection
(Peters et al. 2014; Zaph et al. 2004). More recently, skin resident CD4 T cells
have also been identified in L. major immune mice. These cells remain in the skin
long after the primary infection where they produce IFN-γ in response to the
parasite and recruit circulating T cells in the skin to help further prevent parasite
growth (Glennie et al. 2015). The immunity provided by these multiple subsets of
memory T cells makes them ideal vaccine targets. Additional studies are
necessary to learn about how these cells are maintained.
While we understand the type of immune response generated during
leishmania infection and how parasite replication is controlled, we still do not fully
comprehend how long-lasting immunity is acquired or how to effectively translate
that immunity to a protective vaccine in humans. The treatment for cutaneous
5

leishmaniasis also needs to be improved and may require regulation of the
immune response to achieve effective therapy. In the next section, we discuss
the role of the immune response in the pathogenesis of leishmania infections.

1.3 Immune mediated pathology in cutaneous leishmaniasis
Pathology in cutaneous leishmaniasis is not always a consequence of
uncontrolled parasite growth. In fact, even though patients infected with
leishmania show signs of overt pathology, there are sometimes very few
parasites found in the lesions (Nylen and Eidsmo 2012). Instead, much of the
disease observed in cutaneous leishmaniasis has been associated with immune
mediated pathology. Interestingly, the same immune responses that provide
protection exacerbate the disease when the responses are not controlled. TNF-α
and IFN-γ both help promote the Th1 response necessary to kill leishmania
parasites. Yet, patients with severe, chronic cutaneous and mucocutaneous
leishmaniasis express higher levels of these cytokines (Bacellar et al. 2002;
Gaze et al. 2006; Melby et al. 1994). These studies suggest that the balance
between parasite control and tissue protection must be carefully regulated in
order to limit disease. In fact, patients treated with drugs targeting the TNF-α
pathway in combination with anti-leishmania drugs, experience faster healing
times and higher cure rates than patients with anti-leishmania treatment alone
(Lessa et al. 2001; Bafica et al. 2003; Machado et al. 2007; Ribeiro de Jesus et
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al. 2008). In the treatment of cutaneous leishmaniasis, it is thus necessary to
consider the effects of immunotherapy in addition to anti-parasitic drugs.
Other cytokines have been implicated in mediating pathology during
cutaneous leishmaniasis as well. IL-1β and IL-1α are cytokines produced mainly
by innate cells as well as non-hematopoietic cells, which in the skin are mostly
keratinocytes. While they have important anti-microbial properties, these
cytokines can also lead to skin inflammation in diseases including psoriasis,
atopic dermatitis, and cutaneous lupus erythematous (Mee et al. 2006;
Rauschmayr, Groves, Kupper 1997; Shepherd, Little, Nicklin 2004; Mattii et al.
2013; Nutan, Kanwar, Parsad 2012; Jensen 2010). IL-1 family cytokines, in
particular IL-1β, has also been implicated in mediating disease during cutaneous
leishmaniasis. In humans, IL-1β expression correlates with more severe
cutaneous leishmaniasis (Fernandez-Figueroa et al. 2012; Novais et al. 2014a).
These data suggest that IL-1β plays a role in mediating pathology in the skin.
Yet, how this immunopathology occurs remains unclear. IL-1β can lead to the
production of chemokines, which can recruit inflammatory cells into the skin, and
matrix metalloproteinases, which break down the extracellular matrix and
damages the skin. This relationship between IL-1β and neutrophil recruitment to
lesional skin has also been demonstrated in mice infected with L. major (Voronov
et al. 2010; Gonzalez-Lombana et al. 2013; Charmoy et al. 2016). From these
studies, it is clear that IL-1β and neutrophils exacerbate pathology during
cutaneous leishmaniasis, while having minimal effect on parasite control. IL-1β
recruits neutrophils and other inflammatory cells to the skin, but can also drive
7

the development and maintenance of Th17 cells (Sutton et al. 2006; Yang et al.
2008; Ikeda et al. 2014), which are known to drive inflammation in the skin during
cutaneous leishmaniasis in humans (Souza et al. 2012) as well as in mice (Lopez
Kostka et al. 2009; Anderson et al. 2009; Gonzalez-Lombana et al. 2013). Using
a non-healing mouse model of cutaneous leishmaniasis, our lab has
demonstrated that IL-10 signaling is required to limit an IL-17-mediated
pathology. Although infection with L. major normally resolves in a C57BL/6
mouse, we observed increased ulceration and immunopathology that was not
ameliorated unless we neutralized IL-17. It was previously believed that IFN-γ
and TNF-α were the main drivers of the immunopathology associated with
cutaneous leishmaniasis, however our recent studies indicate that Th17 cells
also play a critical role and warrant further investigation into other factors that
could be important in lesion resolution and pathology (Anderson et al. 2009;
Lopez Kostka et al. 2009; Pitta et al. 2009; Gonzalez-Lombana et al. 2013;
Banerjee et al. 2016)
The lack of regulatory cytokines has proven to be just as important as the
presence of pro-inflammatory cytokines. IL-10, a cytokine known for its ability to
limit inflammation has a prominent role during cutaneous leishmaniasis as it
down-regulates the Th1 response during infection. This role proves important
because it can limit inflammation as well as maintain a low-level of parasites
necessary to develop long-lasting immunity (Belkaid et al. 2001; Belkaid et al.
2002a; Anderson et al. 2007). However, low expression of IL-10 and/or the IL-10
receptor has been associated with more severe disease during cutaneous and
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mucocutaneous leishmaniasis in human patients (Bacellar et al. 2002; Faria et al.
2005; Gaze et al. 2006; Gomes-Silva et al. 2007). While results from the mouse
model can lead to varying results depending on the strain of the mouse, it is
evident that IL-10 is critical in modulating the immune response during cutaneous
leishmaniasis (Kane and Mosser 2001; Gonzalez-Lombana et al. 2013).
T cells produce these pro-inflammatory and anti-inflammatory cytokines
and are some of the main cell types that regulate immune mediated pathology
during cutaneous leishmaniasis. CD4+ T cells are a major source of inflammatory
cytokines including IFN-γ, TNF-α and IL-17 in the skin. And there is clear
evidence that CD4+ T cells mediate pathology during leishmania infections. RAG
deficient mice, which lack T and B cells, are unable to control parasite growth,
yet do not develop skin pathology in response to several species of leishmania
until quite late in the infection (Terabe et al. 1999; Belkaid et al. 2002b; Novais et
al. 2013). However, these mice develop lesions when they receive CD4+ T cell
transfers (Soong et al. 1997) during L. amazonensis infection suggesting that
CD4+ T cells can drive pathology. CD8+ T cells can also be a source of
inflammatory cytokines in the skin. In fact, when transferred into RAG deficient
mice during L. major and L. braziliensis infections, CD8+ T cells lead to
increased pathology with larger lesion development (Belkaid et al. 2002b; Novais
et al. 2013). However, it appears the cytotoxicity, not cytokine production, from
CD8+ T cells is responsible for the tissue damage. During cutaneous
leishmaniasis in humans, cytotoxicity from CD8+ T cells is associated with
ulceration and more severe pathology (Faria et al. 2005; Santos Cda et al. 2013;
9

Novais et al. 2014a; Cardoso et al. 2015). These data combined with studies
using mouse models indicate that while CD8+ T cells can help mediate parasite
control, they are also critical in the immune mediated pathogenesis during
cutaneous leishmaniasis.
During cutaneous leishmaniasis, pro-inflammatory cytokines and the cells
that produce them drive the development of lesions and ulceration in the skin.
This immune mediated pathology is also present in other skin diseases including
psoriasis and atopic dermatitis, in which Th1, Th2, Th17, and cytotoxic CD8+ T
cells all have distinct roles in causing a breakdown in the barrier integrity of the
skin(Di Cesare, Di Meglio, Nestle 2009; Pantelyushin et al. 2012; Martin et al.
2012; Guilloteau et al. 2010; Hijnen et al. 2013; Di Meglio et al. 2016; Hennino et
al. 2007; Hennino et al. 2011). Therapies designed to dampen the inflammatory
response are currently being used in psoriasis and atopic dermatitis, but not to a
large degree in cutaneous leishmaniasis. In cutaneous leishmaniasis,
immunotherapies remain a complicated issue due to the fact that the
development of a protective immune response is necessary to control the
parasite. In this thesis, we will define some of the factors that influence the
immune responses mediating damage to the skin during cutaneous
leishmaniasis.

1.4 The role of Interleukin-22 in skin inflammation
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There are many regulators, positive and negative, of inflammation in the
skin, but one of particular interest is IL-22 due to its role in wound healing and
inflammation in the skin. In the past few years there has been increased focus on
the IL-10 family of cytokines, which consist of IL-10, IL-19, IL-20, IL-26, the λinterferons, and probably its most studied member, IL-22. IL-22 is expressed in
several tissues throughout the body including, the thymus, brain, liver, gut, lung,
pancreas, spleen, and skin, making its potential effects widespread (Dumoutier,
Louahed, Renauld 2000; Wolk et al. 2004). IL-22 is produced by several cellular
sources including, CD4+ T cells, CD8+ T cells, γδ T cells, NKT and NK cells, and
several innate lymphoid cell populations (Wolk et al. 2002; Martin et al. 2009;
Spits et al. 2013; Cella et al. 2009; Goto et al. 2009). Non-lymphoid sources,
including macrophages, neutrophils, and fibroblasts, have been reported, but
may represent a smaller fraction of production (Hansson et al. 2013; Zindl et al.
2013; Ikeuchi et al. 2005).
IL-22 signals through the heterodimer comprised of IL-22R1, a type two
cytokine receptor member of the IL-10 family, and the IL-10R2. Interestingly, IL22 is different from most other interleukins in that it does not act on immune cells.
IL-22R1 expression is limited to non-hematopoietic epithelial cells and
fibroblasts. In the skin keratinocytes and fibroblasts are the main targets of IL-22
(Wolk et al. 2004; Brembilla et al. 2016). The effects of IL-22 on target cells are
mediated through activation of the Jak1/Tyk2 kinases leading to the
phosphorylation of STAT3, primarily, but also STAT1 and STAT5 (Lejeune et al.
2002; Wolk et al. 2004). The activation of these pathways leads to proliferation,
11

migration, and upregulation of pro-survival genes, while it inhibits differentiation
in keratinocytes (Sabat, Ouyang, Wolk 2014). These effects of IL-22 are
important in wound healing, as well as skin inflammation.
As epithelial cells and fibroblasts are the main targets of IL-22, the effects
of this cytokine at barrier surfaces are necessary during tissue repair. During
intestinal damage induced by colitis, IL-22 causes epithelial cells to proliferate
and migrate, ultimately leading to tissue repair and which can protect against
tumor formation (Zenewicz et al. 2008; Pickert et al. 2009; Huber et al. 2012).
During HIV and SIV infections, IL-22 limits epithelial damage in the intestine and
protects against bacterial translocation (Klatt et al. 2012; Kim et al. 2012).
Similarly, IL-22 contributes to protection and regeneration of lung epithelial cells
during influenza infection (Kumar et al. 2013; Paget et al. 2012; Pociask et al.
2013). This protection also prevented secondary bacterial infections (Ivanov et al.
2013). These effects of IL-22 are also seen in the skin. Keratinocytes are the
main target of IL-22 in the skin. Using an in vitro injury model, one study
demonstrated that IL-22 induced proliferation and migration of keratinocytes to
induce wound closure after damage (Boniface et al. 2005). IL-22 also limits the
differentiation of keratinocytes (Boniface et al. 2005; Wolk et al. 2006; Wolk et al.
2009). While continually blocking differentiation could inhibit wound healing, it is
helpful in the initial stages when keratinocytes need to regenerate the basal layer
of the epidermis. Fibroblasts can also respond to IL-22 and contribute to wound
healing after injury. IL-22 induces myofibroblast differentiation and helps with
wound closure in an acute injury model (McGee et al. 2013). Wound healing is
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an important feature during cutaneous leishmaniasis involving a regulated
response of keratinocyte survival, fibroblast maturation, and collagen deposition
(Eidsmo et al. 2005; Eidsmo et al. 2007; Tasew et al. 2010; Almeida et al. 2015;
Sakthianandeswaren et al. 2005; Baldwin et al. 2007; Elso et al. 2004b; Elso et
al. 2004a), but whether IL-22 has these effects during infection are not yet
known.
The effects of IL-22 on wound healing can also lead to inflammation and
pathology depending on the context. In addition to inducing proliferation and
migration, IL-22 also induces chemokine expression in epithelial cells.
Neutrophilic-attracting chemokines like CXCL1, CXCL2, CXCL5, and CXCL8 are
induced in epithelial cells after exposure to IL-22 (Aujla et al. 2008; Wolk et al.
2009). These chemokines create a cascade of inflammation that can cause more
damage than repair. These effects are amplified in combination with other
inflammatory cytokines including IL-17, TNF-α, and IFN-γ (Wolk et al. 2004; Wolk
et al. 2009; Guilloteau et al. 2010). In fact, IL-22 limits lung injury in the absence
of IL-17, while driving inflammation when IL-17 is present (Sonnenberg et al.
2010). The balance between protection and pathology must also be regulated
during cutaneous leishmaniasis, and IL-22 may play a role in that process.
IL-22 also causes inflammation and pathology in the skin. Mice that
constitutively express IL-22 or have IL-22 injected into their skin develop severe
inflammation in the skin, similar to what is observed during psoriasis and atopic
dermatitis (Zheng et al. 2007; Wolk et al. 2009; Ma et al. 2008; Van Belle et al.
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2012; Wang et al. 2013). Similar to what is observed during tissue repair, IL-22
induces keratinocyte proliferation during inflammatory skin disorders. However in
this scenario, hyperproliferation leads to acanthosis and inflammation that
worsens the pathology.
IL-22 also has antimicrobial effects at barrier surfaces. In the intestine,
lung, and skin, IL-22 induces the expression of antimicrobial peptides in the βdefensins, S100, and Reg families (Wolk et al. 2004; Zheng et al. 2008; Wolk et
al. 2006; Aujla et al. 2008; Brand et al. 2006; Sekikawa et al. 2010). These
antibacterial actions lead to protection from invading pathogens, but also regulate
the commensal populations in the intestinal tract (Sonnenberg et al. 2012;
Zenewicz et al. 2013). However, the modulation of the commensal population
does not always lead to protection. IL-22 induces the expression of antimicrobial
peptides that suppress Enterobacteriaceae colonization by nutrient sequestration
in the intestine. However, in the absence of this commensal, the pathogen
Salmonella enterica is able to better colonize and cause inflammation (Behnsen
et al. 2014). During infection with the parasite Toxoplasma gondii, IL-22 also
drives inflammation in the intestinal tract (Munoz et al. 2009; Wilson et al. 2010),
but whether it is due to an imbalance in the commensal bacteria is unknown.
Commensal bacteria on the skin drive an inflammatory response that could lead
to lesion development in cutaneous leishmaniasis (Naik et al. 2012), but whether
the anti-microbial effects of IL-22 can regulate this process is unknown.
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IL-22 is an active member of the IL-10 cytokine family at barrier surfaces.
The roles of IL-22 in the skin, gut, lung, and liver have demonstrated that this
cytokine can affect the outcomes of injury, infection, and inflammation in a variety
of ways. During cutaneous leishmaniasis, the processes of wound healing and
inflammation must be tightly regulated in order to successfully resolve lesions
and control parasite replication. The actions of IL-22 on the skin immunity may be
a key player in these processes.

1.5 The microbiota and skin immunity
The microbiota is the collective populations of bacteria, viruses, fungi,
protozoa and archaea found in our environment or associated with various
tissues and organs throughout our body. It has been estimated that there are
from 3-10 times more bacterial cells in the body than human cells (Woese 1987;
Sender, Fuchs, Milo 2016), and it is evident that the microorganisms associated
with our body are important players in our biology. Bacteria are found in or on
many parts of the body, including the intestinal tract, skin, mouth, and the
reproductive tract. While the exact numbers may vary depending on size and
gender of the person, early studies suggested that the intestinal tract harbored
the most bacteria with about 1014 cells, followed by the skin with about 1012 cells,
while the rest of the body sites harbor around 1012 bacteria combined (Savage
1977; Berg 1996). Many studies have focused on the bacteria in the intestinal
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tract, but recently studying the commensal bacteria on the skin has become a
larger area of interest.
Prior to the age of genomics, culture based methods were used to study
the bacteria in the environment. However, it became apparent that simply
culturing samples was not capturing all the bacteria present (Amann, Ludwig,
Schleifer 1995; Staley and Konopka 1985). The discovery that bacterial
phylogeny could be determined based on the well-conserved 16S ribosomal RNA
(rRNA) gene (Woese 1987) set the stage for the present-day microbiota studies.
Presently, bacterial communities are identified using high-throughput
sequencing. The Human Microbiome Project was started in 2007 and collected
over 200 samples across various body sites in order to define the microbiota of
healthy adults. This study used 16S rRNA gene and whole genome sequencing
to demonstrate that the different body sites harbored distinct, yet diverse
bacterial communities (NIH HMP Working Group et al. 2009). This study, along
with many others that followed, suggested that a healthy microbiota is typically a
diverse one.
Subsequent studies have shown that perturbations in the microbiota, often
referred to as dysbiosis, are associated with disease and inflammation. This
association with disease and dysbiosis has been observed during inflammatory
bowl disorders, metabolic disorders, cancer, as well as inflammatory skin
diseases (Sartor 2009; Garrett et al. 2010; Ley et al. 2005; Turnbaugh et al.
2006; Castellarin et al. 2012; Gao et al. 2008; Kong et al. 2012). While many of
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these studies show only correlations between dysbiosis and disease, more
recent research has focused on determining whether dysbiosis is a cause or
consequence of disease. A lot of those studies have focused on the intestinal
tract. Bacteria in the intestinal tract that cause dysbiosis have been shown to
drive disease in arthritis, obesity, cancer, and colitis (Wu et al. 2010; Turnbaugh
et al. 2006; Wu et al. 2009; Sellon et al. 1998; Elinav et al. 2011a; Zenewicz et al.
2013). These effects are often mediated through modulation of immune
responses. Interestingly, there is also evidence that dysbiosis can drive an
immune regulatory phenotype and protect against disease in the intestine
(Atarashi et al. 2013). It is evident that the intestinal microbiota interacts with the
immune system to either drive disease, or protect the host from inflammation. It
is not yet evident that the microbiota on the skin are also as important in
diseases.
While it is clear that the bacteria on the skin are quite numerous, less is
known about how those microorganisms influence immunity in the skin. The
diversity of the skin microbiota depends on the body site as well as what type of
environment is present at that site. For example, oily, dry, and moist body sites
all harbored distinct bacterial communities (Grice et al. 2009). This difference in
the types of microbes on different body sites was also observed in fungal and
viral communities (Findley et al. 2013; Hannigan et al. 2015). While these studies
demonstrated that healthy skin sites typically have diverse microbial populations,
the same is not always true during disease in the skin.
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Inflammatory skin disorders, including atopic dermatitis, psoriasis, and
chronic diabetic wounds, have been associated with changes in the skin
microbiota (Kong et al. 2012; Alekseyenko et al. 2013; Gao et al. 2008; Price et
al. 2009; Grice et al. 2010; Loesche et al. 2016). However, it is not clear what
causes these changes. During inflammation, cytokines, chemokines, and
antimicrobial peptides are often produced, potentially explaining why there are
changes in the microbiota. Some bacteria, like Salmonella typhimurium and
Escherichia coli, can utilize products of the immune response by changing their
metabolic processes. This adaptation allows them to thrive in the face of
inflammation, ultimately leading to dysbiosis in the microbiota (Winter et al. 2010;
Behnsen et al. 2014; Hughes et al. 2017). This phenomenon is apparent in the
intestine (Atherton and Blaser 2009; Behnsen et al. 2014), but it remains unclear
whether it occurs in the skin.
But what is clear is that the skin microbiota can influence the cutaneous
immune response. Recent studies have shown that prominent members of the
skin microbiota, for example, Staphylococcus spp. can drive inflammatory Th1
and Th17 responses in the skin. In some cases the cytokines from these cells
can lead to protection from a pathogen (Naik et al. 2015), while driving
inflammation in response to other pathogens, including L. major infection (Naik et
al. 2012). Bacteria can even drive the development of regulatory responses in
the early stages of life that help limit inflammation during infection experienced as
an adult (Scharschmidt et al. 2015). These studies demonstrate how colonization
with bacteria can influence skin immunity, but it is unknown whether naturally
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occurring dysbiosis has any influence on skin disease. There is some evidence
of dysbiosis driving disease in atopic dermatitis (Kobayashi et al. 2015), but
whether dysbiosis occurs during leishmania infection or influences disease in
cutaneous leishmaniasis remains
unknown.
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Figure 1. Leishmania transmission, control, and role in immune mediated pathology. (a)
Sandflies transfer leishmania parasites into the skin upon blood feeding. The parasite is taken up
by phagocytic cells, where it can replicate and spread to other cells. The parasite is transmitted
back into the sandfly upon another blood feeding. (b) IL-12 production from dendritic cell induces
IFN-γ production from T cells and NK cells. IFN-γ activates infected cells to kill the parasite. (c)
During infection, inflammatory cytokines are produced by T cells. These cytokines recruit
inflammatory monocytes and neutrophils, which make IL-1α and IL-1β. The recruitment of these
inflammatory cells ultimately lead to tissue damage. IL-10 can limit this pathology by blocking
cytokine production from T cells.

1.6 Summary
It is clear that the magnitude of the disease associated with leishmania
infections is not only mediated by parasite replication, but also includes the
19

immune response as a major cause of pathology. Several cytokines have been
identified to regulate inflammation during cutaneous leishmaniasis. Inflammatory
cytokines, IL-1β, TNF-α, IFN-γ, and IL-17 all seem to mediate tissue damage in
the course of infection with leishmania parasites. On the other hand, regulatory
cytokines like IL-10 are also important to limit the actions of the inflammatory
cytokines.
Limiting inflammation and establishing a wound healing response is
required to resolve cutaneous leishmaniasis lesions (Baldwin et al. 2007; Elso et
al. 2004a; Elso et al. 2004b). IL-22 is a cytokine of interest because of its dual
roles in inflammation and wound healing. While there is some evidence that IL-22
is associated with protection during visceral leishmaniasis (Pitta et al. 2009;
Ghosh et al. 2013), the role of IL-22 is less well studied during cutaneous
leishmaniasis. Here, we will investigate the role of IL-22 during cutaneous
leishmaniasis to determine if it is involved in driving inflammation or limiting
disease. IL-22 can also regulate the commensal microbiota, another potential
way it can affect the immune response in the skin. While there are varying results
describing the effects of the microbiota during cutaneous leishmaniasis (de
Oliveira et al. 1999; Oliveira et al. 2005; Naik et al. 2012), it is clear that the skin
microbiota have a role during this disease. Here, we will investigate whether the
microbiota is influenced by cutaneous leishmaniasis and if those naturally
occurring changes influence the outcome of disease. The goals of these studies
are designed to better understand what factors mediate immunopathology during
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cutaneous leishmaniasis, with the hope to develop more effective therapies for
the disease.
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CHAPTER 2: IL-22 PROTECTS AGAINST TISSUE DAMAGE DURING
CUTANEOUS LEISHMANIASIS

2.1 Abstract
Cutaneous leishmaniasis is a disease characterized by ulcerating skin
lesions, the resolution of which requires an effective, but regulated, immune
response that limits parasite growth without causing permanent tissue damage.
While mechanisms that control the parasites have been well studied, the factors
regulating immunopathologic responses are less well understood. IL-22, a
member of the IL-10 family of cytokines, can contribute to wound healing, but in
other instances promotes pathology. Here we investigated the role of IL-22
during leishmania infection, and found that IL-22 limits leishmania-induced
pathology when a certain threshold of damage is induced by a high dose of
parasites. Il22-/- mice developed more severe disease than wild-type mice, with
significantly more pathology at the site of infection, and in some cases
permanent loss of tissue. The increased inflammation was not due to an
increased parasite burden, but rather was associated with the loss of a wound
healing phenotype in keratinocytes. Taken together, these studies demonstrate
that during cutaneous leishmaniasis, IL-22 can play a previously unappreciated
role in controlling leishmania-induced immunopathology.
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2.2 Introduction
Cutaneous leishmaniasis is a major neglected tropical disease affecting
about 12 million people globally (Kedzierski 2010). The spectrum of clinical
manifestations in cutaneous leishmaniasis ranges from self-limiting nodules to
non-healing ulcers with a highly inflammatory immune response, and the disease
is caused by several different species of leishmania that reside within phagocytic
cells. Control of the parasites requires IFN-γ produced by CD4+ Th1 cells (Wang
et al. 1994). However in spite of a Th1 response, some patients exhibit severe
non-healing lesions (Bacellar et al. 2002; Gaze et al. 2006). Thus, in addition to
controlling the parasites, regulating the inflammatory response is essential for
disease control. TNF-α (Antonelli et al. 2005; Bafica et al. 2003), IL-1β
(Fernandez-Figueroa et al. 2012; Voronov et al. 2010) and IL-17 (GonzalezLombana et al. 2013; Lopez Kostka et al. 2009) have all been implicated in
promoting pathology in leishmaniasis, and damage caused by cytolytic CD8 T
cells can also contribute to these immunopathologic responses (Crosby et al.
2014; da Silva Santos et al. 2014; Novais et al. 2013; Novais et al. 2014a). IL-10
can regulate some of these immunopathologic responses (Faria et al. 2005;
Gonzalez-Lombana et al. 2013). Since drug treatment is often ineffective (Bafica
et al. 2003), and no human vaccine exists for the disease, a better understanding
of the factors that mediate lesion resolution is essential to help develop new
immunotherapies for the disease.
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Recently, members of the IL-10 subfamily have been identified as key
players in the wound healing process (Sa et al. 2007; Sun et al. 2013; Wolk et al.
2002). IL-22 is a prominent member of this family, and can instruct non-immune
cells, such as epithelial cells and fibroblasts, to proliferate, migrate, and mend the
extracellular matrix after injury (Boniface et al. 2005; McGee et al. 2013). These
functions are important in maintaining surface barrier integrity and protection
against subsequent infections. Additionally, IL-22 has been shown to induce the
production of antimicrobial peptides from epithelial cells in order to maintain a
balanced commensal population and prevent dysbiosis (Sonnenberg et al. 2011;
Zenewicz et al. 2013; Zheng et al. 2008). However, while IL-22 is important for
tissue protection and contributes to wound healing in the skin, gut, and lungs
(Aujla et al. 2008; McGee et al. 2013; Pickert et al. 2009), it can also be
pathogenic in other inflammatory conditions, such as psoriasis(Van Belle et al.
2012). These pathologic responses are mediated by some of the same functions
of IL-22 that are protective, including uncontrolled proliferation and the production
of inflammatory molecules(Ma et al. 2008; Sonnenberg et al. 2010; Van Belle et
al. 2012; Zheng et al. 2007). Why IL-22 is protective in some situations and
pathologic in others is unclear, but may depend on the amount of IL-22
produced, as well as the presence of other inflammatory cytokines such as IL-17
(Guilloteau et al. 2010; Sonnenberg et al. 2010).
Like in some patients, the lesions of C57BL/6 mice normally heal after L.
major infection. In order to determine if IL-22 contributes to resolution of a
leishmanial infection, we infected Il22-/- mice with Leishmania major and L.
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braziliensis and monitored the course of infection. We found that Il22-/- mice
exhibited increased tissue pathology compared with infections in wild-type mice.
The absence of IL-22 did not influence the parasite burden, but rather led to
higher levels of keratin 6a and keratin 16, both of which have been implicated in
inhibiting the wound healing capabilities of keratinocytes (Rotty and Coulombe
2012; Wawersik et al. 2001). We discovered that a role for IL-22 was only evident
with high doses of parasites, suggesting that a threshold of inflammation might
have to be reached before IL-22 contributed to tissue protection. Taken together,
our results demonstrate a previously unknown role for IL-22 in limiting pathology
during leishmania infection.

2.3 Materials and methods

Ethics statement
This study was conducted according to the principles specified in the
Declaration of Helsinki and under local ethical guidelines (Ethical Committee of
the Maternidade Climerio de Oliveira, Salvador, Bahia, Brazil; and the University
of Pennsylvania Institutional Review Board). This study was approved by the
Ethical Committee of the Federal University of Bahia (Salvador, Bahia, Brazil)
(010/10) and the University of Pennsylvania IRB (Philadelphia, PA) (813390). All
patients provided written informed consent for the collection of samples and
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subsequent analysis. This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved by the Institutional
Animal Care and Use Committee, University of Pennsylvania Animal Welfare
Assurance Number A3079-01.

Mice
Female C57BL/6 mice 6-8 weeks old were purchased from the National Cancer
Institute (Frederick, MD). B6.IL22 (Il22-/-) were donated by Pfizer (Cambridge,
MA). All mice were maintained in specific pathogen-free facilities at the University
of Pennsylvania. Prior to infection, mice were anesthetized using a ketamine and
xylazine mixture and monitored until mice were fully awake. At the end of the
experiments, mice were humanely euthanized using carbon dioxide inhalation.
All procedures were performed in accordance with the guidelines of the
University of Pennsylvania Institutional Animal Care and Use Committee
(IACUC).

Parasite and infection
L. major (WHO /MHOM/IL/80/Friedlin wild-type L. major) and L.
braziliensis (MHOM/BR/01/BA788) (de Moura et al. 2005) promastigotes were
grown to the stationary phase in Schneider’s Drosophila medium (GIBCO BRL,
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Grand Island, NY, USA) supplemented with 20% heat-inactivated fetal bovine
serum (FBS, Invitrogen USA), 2 mM L-glutamine, 100 U of penicillin and 100 µg
of streptomycin per mL. Infective-stage promastigotes (metacyclics) were
isolated from 4-5 day old (L. major) and 7 day old (L. braziliensis) stationary
culture by density gradient separation by Ficoll (Sigma) (Spath and Beverley
2001). Mice were inoculated intradermally in the ear with 10 uL of PBS
containing 2 x 106 L. major metacyclic promastigotes. In some experiments mice
were infected with a low does of parasite (2 x 103) or a super-high dose of
parasites (2 x 107). Lesion development was measured weekly by ear thickness
with a digital caliper (Fisher Scientific). Mice were also assessed for pathology,
using the following score system: no lesion (0), swelling/redness (1), deformation
of the ear pinna (2), ulceration (3), partial tissue loss (4), and total tissue loss (5).
Parasite burden in lesion tissues was assessed using a limiting dilution assay as
previously described (Zaph et al. 2004). Freeze-thawed antigen (FTAg) was
obtained from stationary-phase promastigotes of L. major. Soluble leishmanial
antigen (SLA) was prepared from L. braziliensis parasites are previously
described(Reed et al. 1986).

Patients and recall assays
All cutaneous leishmaniasis patients were seen at the health post in Corte
de Pedra, Bahia, Brazil, which is a well-known area of L. braziliensis
transmission. The criteria for diagnosis were a clinical picture characteristic of
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cutaneous leishmaniasis in conjunction with parasite isolation or a positive
delayed-type hypersensitivity response to Leishmania antigen, plus histological
features of cutaneous leishmaniasis. In all cases, the immunological analysis
was performed before therapy. For cell culture and IL-22 measurement,
peripheral blood mononuclear cells (PBMCs) were obtained from heparinized
venous blood layered over a Ficoll-Hypaque gradient (GE Healthcare), then
washed and resuspended in RPMI1640 medium with 10% heat inactivated
human AB serum (Sigma) at a concentration of 3 x 106 cells/mL. These cells
were added to 24-well plates and were kept unstimulated or were stimulated with
soluble leishmania antigen (5 ug/mL) for 96 h at 37C in 5% CO2. The
supernatants were collected and stored frozen until analyzed for cytokines. IL-22
was measured by enzyme-linked immunosorbent assay (Pfizer).

Preparation of dermal sheets
The dorsal and ventral sides of the mouse ear were split mechanically and
placed dermis side down in a 24 wells plate in RPMI 1640 containing 0.25 mg/mL
of Liberase TL (Roche, Diagnostics Corp.) and 10 mg/mL DNase I (SigmaAldrich). Ears were incubated for 90 min at 37° C in a 24-well plate. Dermal cell
suspensions were prepared by dissociation on 70- um cell strainer (Falcon) in
PBS containing 0.05% BSA and 20 mM EDTA.
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In vitro restimulation and cytokine measurements
For measurements of antigen-specific cytokine production in the mouse,
the retroauricular lymph node was removed, mechanically dissociated, and single
cell suspensions were prepared. Cells were resuspended in RPMI 1640
supplemented with 10% of FBS, 2 mM L-glutamine, 100 U of penicillin and 100
µg of streptomycin per mL and 0.05 mM of b-mercaptoethanol. 4 x106 cells per
mL were plated in 24-well plates. Cells were incubated at 37°C in 5% CO2 with
20 x106 L.major or L. braziliensis FTAg/mL. Supernatants were harvested 72 h
after stimulation and assayed using a sandwich enzyme-linked immunosorbent
assay (ELISA) for IFN-γ (eBioscience), IL-17 (eBioscience), and IL-22 (Pfizer).
Cytokine concentrations were calculated from standard curves with a detection
limit of 0.030 ng/mL.

Antibodies and flow cytometry
Single cell suspensions from the ear were obtained as described above.
For analysis of surface markers and intracellular cytokines, some cells were
incubated for 4 h with 10 mg/mL of brefeldin A, 50 ng/mL of PMA and 500 ng/mL
ionomycin (Sigma-Aldrich). Before staining, cells were incubated with an antiFcg III/II receptor and 10% rat-IgG in PBS containing 0.1% BSA. Cells were
stained for dead cells (Invitrogen) and surface markers (CD4, CD8b [BioLegend],
CD45, Ly6G, CD11b [eBioscience]) followed by fixation with 2% of formaldehyde.
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The data were collected using LSRII flow cytometer (BD) and analyzed using
FlowJo software (Tree Star).

RNA isolation, purification, and quantitative real-time PCR
Total RNA was extracted from ear tissue samples in 700uL of RLT lysis
buffer (Qiagen). The sample was homogenized using a tissue homogenizer
(FastPrep-24, MP Biomedical), and total RNA was extracted according to the
recommendations of the manufacturer and further purified using the RNeasy Mini
kit (QIAGEN). RNA was reverse transcribed using high capacity cDNA Reverse
Transcription (Applied Biosystems). Real-time RT-PCR was performed on a
ViiA™ 7 Real-Time PCR System (Applied Biosystems). Relative quantities of
mRNA for several genes was determined using SYBR Green PCR Master Mix
(Applied Biosystems) and by the comparative threshold cycle method, as
described by the manufacturer. mRNA levels for each sample were normalized
to Ribosomal protein S11 gene (RPS11). Primers were designed using Primer
Express software (version 2.0; Applied Biosystems); Rps11, forward, 5’CGTGACGAAGATGAAGATGC-3’ and reverse, 5’GCACATTGAATCGCACAGTC-3’; Krt5, forward, 5'TTTGCCTCCTTCATCGACA-3' and reverse, 5'-CGGATCCAGGTTCTGCTTTA3'; Krt14, forward, 5'-ATCGAGGACCTGAAGAGCAA-3' and reverse, 5'TCGATCTGCAGGAGGACATT-3'; Krt6a, forward, 5'GAGGAGAGGGAGCAGATCAA-3' and reverse, 5'30

CACTTGGTGTCCAGGACCTT-3'; Krt16, forward, 5'TTGAGGACCTGAAGAGCAAGA-3' and reverse, 5'CCTGGCATTGTCAATCTGC-3'; Il22, 5'-ATGAGTTTTTCCCTTATGGGGAC-3'
and reverse, 5'-GCTGGAAGTTGGACACCTCAA-3'; Il22bp, forward, 5'TCAGCAGCAAAGACAGAAGAAAC-3' and reverse, 5'GTGTCTCCAGCCCAACTCTCA-3'; Ifng, forward, 5'GACTGTGATTGCGGGGTTGT-3' and reverse, 5'GGCCCGGAGTGTAGACATCT-3'; Il4, forward, 5'ATGGAGCTGCAGAGACTCTT-3' and reverse, 5'AAAGCATGGTGGCTCAGTAC-3'; Il17, forward, 5'CATGAGTCCAGGGAGAGCTT-3' and reverse, 5'GCTGAGCTTTGAGGGATGAT-3'; Il12p40, forward, 5'TTGAAAGGCTGGGTATCGGT-3' and reverse, 5'GAATTTCTGTGTGGCACTGG-3', Tnfa, forward, 5'TCACTGGAGCCTCGAATGTC-3' and reverse, 5'GTGAGGAAGGCTGTGCATTG-3'; Il6, forward, 5’ACAGAAGGAGTGGCTAAGGA-3’ and reverse, 5’-CACCATGGAGCAGCTCAG3’; Il10, forward, 5'-TGTCCAGCTGGTCCTTTGTT-3’ and reverse, 5'ACTGCACCCACTTCCCAGT-3'; Tgfb, forward, 5’CGCTGCTACTGCAAGTCAGA-3’ and reverse, 5’GGTAGCGATCGAGTGTCCA-3’; Il27p28, forward, 5'GATTGCCAGGAGTGAACCTG-3' and reverse, 5'CGAGGAAGCAGAGTCTCTCAG-3'; Il1a, forward, 5’31

TTGGTTAAATGACCTGCAACA-3’ and reverse, 5’GAGCGCTCACGAACAGTTG-3’; Il1b, forward, 5’-TTGACGGACCCCAAAAGAT3’ and reverse, 5’- GATGTGCTGCTGCGAGATT-3’.

Microbiota collection, sequencing, and analysis
Two independent experiments were performed using littermates as
controls, with n=9-10 mice per cohort for a total of 9 Il22-/- mice, 3 Il22+/- mice,
and 7 Il22+/+ mice. Microbiota was collected from the ear of the mouse using a
swab (Catch-all Sample Collection Swab, Epicentre) moistened in Yeast Cell
Lysis Buffer (from MasterPure Yeast DNA Purification Kit; Epicentre). DNA was
isolated from swab specimens and amplification of the 16S-V4 region was
performed as previously described (Hannigan et al. 2014). Sequencing of 16S
rRNA amplicons was performed at the Penn Next Generation Sequencing Core
using the Illumina MiSeq platform with 150 bp paired-end ‘V2’ chemistry.

Pre-processing and community characterization of 16S rRNA gene
sequence data
Sequence pre-processing followed methods previously described
(Hannigan et al. 2014), but modified by subsampling at 11,000 sequences per
sample. QIIME 1.6.0 (Caporaso et al. 2010) was used for initial stages of
sequence analysis. Sequences were clustered into OTUs (operational taxonomic
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units, a proxy for ‘species’) using UCLUST(Edgar 2010) at 97% sequence
similarity. Bacterial diversity was calculated using the following alpha diversity
indices: 1) Shannon diversity index; 2) Faith’s phylogenetic distance (PD); and 3)
Chao I species estimation; and 4) number of observed OTUs. Relative
abundance of bacteria was calculated based on taxonomic classification of
sequences using the RDP classifier (Wang et al. 2007) at a confidence threshold
of 0.8. Microbiota data was analyzed with the R statistical software environment
(ww.r-project.org). Statistical significance was determined using two-sample
Wilcoxon tests and corrected for multiple comparisons by FDR where
appropriate.

Statistical analysis
Results represent means ± SEM. Data were analyzed using Prism 5.0
(GraphPad Software, San Diego, CA). Statistical significance was determined by
one-way ANOVA when comparing more than two groups and by an unpaired
two-tailed Student’s t test to compare means of lesion sizes, parasite burdens,
and cytokine production from different groups of mice. Statistically significant
differences were defined as * when p values <0.05.

2.4 Results
Leishmania infections induce the production of IL-22
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Since IL-22 can have tissue protective effects, we investigated whether IL22 might help control pathology during infection with leishmania. We first asked
whether infection with leishmania parasites led to an increase in IL-22
production. C57BL/6 (wild-type) mice were infected with L. major and were
euthanized at 3 days, 2 weeks or 5 weeks after infection. Cells from the draining
lymph nodes were stimulated with leishmanial antigen and cytokine levels were
assessed. As expected during infection with L. major, IFN-γ and IL-17 were
produced in an antigen dependent manner (Figure 2a-b). As early as 3 days after
infection there was an antigen specific production of IL-22, which was maintained
at 2 and 5 weeks post-infection (Figure 2c). Because we know CD4+ T cells can
be a major source of IL-22 (Liang et al. 2006; Zheng et al. 2007), we wanted to
determine if CD4+ cells contributed to the antigen-specific production of IL-22
during L. major infection. Thus, C57BL/6 mice were infected with L. major and
depleted of CD4+ cells in vivo using a neutralizing antibody 2 days prior to
sacrificing the mice. Cells were harvested from the draining lymph nodes at 3
days post-infection and cultured with media alone or with L. major antigen for 72
hours. Antigen stimulated cells from anti-CD4 treated mice produced significantly
less IL-22 than untreated mice (Figure 2d), demonstrating that the production of
IL-22 is dependent on the presence CD4+ T cells. We also observed the
production of IL-22 from cells of mice infected with another species of the
parasite, L. braziliensis (data not shown). To determine if patients infected with L.
braziliensis parasites also produced IL-22, peripheral blood mononuclear cells
(PBMCs) from leishmaniasis patients were isolated and cultured with leishmanial
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antigen. Similar to cells from mice, PBMCs from infected patients, but not healthy
subjects, produced IL-22 in response to stimulation with leishmanial antigen
(Figure 2e), suggesting that IL-22 may be important in human patients as well as
in experimental murine infections.

IL-22 limits pathology during leishmania infection independent of parasite
control
To determine if IL-22 plays a protective role during the course of infection
with leishmania, C57BL/6 and Il22-/- mice were infected with L. major and the
disease monitored. Il22-/- mice exhibited larger lesions compared with wild-type
mice (Figure 3a). We noticed that in addition to greater swelling, the ears of Il22-/mice often exhibited more severe pathology than wild-type mice, and in some
cases led to tissue loss at the site of infection (Figure 3b). To quantify these
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Figure 2: IL-22 is induced during leishmania infections. C57BL/6 mice were intradermally
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changes, we employed a scoring system that better captures the pathology
associated with leishmania infection. As seen in Figure 3c, Il22-/- mice exhibited
greater pathology than wild-type mice infected with L. major. To determine if the
increased pathology observed following L. major infections was due to higher
parasite levels in Il22-/- mice, we assessed the parasite burden in wild-type and
Il22-/- mice at 2, 5 and 12 weeks of infection, and found no significant differences
(Figure 3d).
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L. braziliensis parasites are known to induce a particularly strong
inflammatory response in patients, and also cause mucosal leishmaniasis, the
most severe form of the disease (de Oliveira and Brodskyn 2012). Therefore, we
asked if IL-22 regulated the lesion resolution in this infection as well. We infected
wild-type and Il22-/- mice with L. braziliensis and followed the course of infection.
As with L. major, L. braziliensis infected Il22-/- mice had significantly larger
lesions than wild-type mice with more pathology, but no differences in the
number of parasites within the lesions (Figure 3e-f).

IL-22 maintains wound-healing capabilities in the skin during L. major
infection
The resolution of a leishmanial lesion is analogous to wound healing,
which requires keratinocyte proliferation and differentiation (Martin 1997).
Therefore, we analyzed the expression of several genes at the peak of infection
to assess keratinocyte functions in the lesions of wild-type and Il22-/- mice. We
observed no difference in the expression of keratin 5 and keratin 14, both of
which are expressed in proliferating keratinocytes, between wild-type and Il22-/mice (Figure 4a). We then decided to look at other keratins, which are
upregulated in chronic wounds and can inhibit the ability of keratinocytes to
efficiently heal
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mean ± SEM, *p < 0.05.
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wounds and damage (Rotty and Coulombe 2012; Wawersik et al. 2001). We
observed that Il22-/- mice had higher expression of keratin 6a and keratin 16
(Figure 4b), both of which are known to inhibit keratinocytes migration. Thus, one
role of IL-22 during cutaneous leishmaniasis may be to promote wound healing
capabilities of keratinocytes by regulating the expression of keratins involved in
migration and differentiation.

The requirement for IL-22 depends on parasite burden and inflammation
Recently, it was reported that IL-22 does not play a role during a low dose
of infection with L. major (Brosch et al. 2014). Our results, taken together with
other findings prompted us to consider the possibility that IL-22 might only be
required when a threshold of inflammation and tissue damage was present. To
test this hypothesis, we infected mice with a super high dose of parasites (2 x
107), an intermediate dose (2 x 106), and with a low dose of parasites (2 x 103),
and followed the course of infection. Because we noticed some variability
between experiments, we decided to pool data from multiple experiments and
compare pathology at the peak of infection. Similar to recent findings in which
mice were infected with a low dose of parasites(Brosch et al. 2014), we observed
no difference in the lesion size or pathology between wild-type and Il22-/- mice
when infected with 2 x 103 parasites (Figure 5a). On the other hand, Il22-/- mice
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Figure 4: IL-22 regulates the expression of skin repair genes during L. major infection. (a-/6
b) Wild-type and Il22 mice were intradermally infected with 2 x10 L. major promastigote
metacyclics and RNA was isolated from the lesions at 5 weeks post-infection to assess gene
expression. Data are represented as relative expression to housekeeping gene rps11 and are
representative of at least 2 independent experiments, with 3-5 mice per group. Error bars indicate
mean ± SEM, *p < 0.05.

infected with 2 x 106 and 2 x 107 parasites had more pathology than their wildtype counterparts (Figure 5b-c). We euthanized these animals at 5 weeks postinfection and assessed their parasite burdens. As expected from the results
described above, no differences were observed in the parasite burden between
wild-type and Il22-/- mice (data not shown). We then measured levels of IL-22
expression in the lesions, and found significantly higher expression of Il22 mRNA
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when mice were infected with more parasites (Figure 5d). The IL-22 binding
protein (IL-22BP) is a soluble receptor that inhibits IL-22 signaling through its
receptors (Xu et al. 2001). Thus, we examined the expression of Il22BP in wildtype mice infected with L. major infection. Unlike IL-22, IL-22BP was expressed
at significantly lower levels when mice were infected with more parasites (Figure
5e). These results suggest that following infection with high numbers of parasites
IL-22 is induced to a greater extent and less inhibited by IL-22BP, and that IL-22
helps regulate the pathology associated with a higher parasite burden.

IL-22 does not modulate the skin microbiota at the steady state
Recent studies indicate that the skin microbiota influences the pathology
associated with leishmania infection (Naik et al. 2012). Since IL-22 regulates the
production of antimicrobial peptides (AMPs) (Liang et al. 2006; Sonnenberg et al.
2012), we considered the possibility that homeostatic levels of IL-22 might
influence AMP levels, resulting in changes in the skin microbiota and
consequently disease development. To test this idea, the ears of uninfected
Il22+/+/Il22+/- and Il22-/- littermates were swabbed to extract bacterial DNA. 16S
ribosomal RNA genomic sequencing was performed and the skin microbiota was
analyzed. In two independent experiments (n=9 Il22-/- mice and n=10 control
littermate mice) no significant differences in bacterial diversity were observed
between littermate controls and Il22-/- mice (Figure 6a). There were also no
differences in the relative abundance of the bacterial communities between
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controls and Il22-/- mice (Figure 6b). These findings indicate that Il22-/- mice do
not have a dysbiotic skin microbiota responsible for the increased pathology.

IL-22 does not regulate inflammatory cell infiltrate, but rather limits tissue
damage during L. major infection.
Because we observed more pathology and inflammation in the Il22-/- mice, we
wanted to determine if there was increased inflammatory cell infiltrate in the
lesions of these mice. We examined the presence of CD4+ and CD8+ T cells,
CD11b+ myeloid cells, and neutrophils in the lesions of L. major infected wildtype and Il22-/- mice at the peak of infection. While there was an increase over
naïve skin in the frequency and numbers of T cells of wild-type and Il22-/- lesions
and in the numbers of myeloid cells, there was no difference in these populations
between wild-type and Il22-/- mice (Figure 7a). We also assessed transcript levels
of inflammatory and regulatory cytokines in the lesions of wild-type and Il22-/mice. As expected, Ifng levels were increased following infection, and there was
a similar increase in wild-type and Il22-/- mice. There were minimal or no changes
in Il4, Il17, Tnfa, Il12a, Il6, Il10, Tgfb and Il27p28 gene expression between naïve
skin and leishmanial lesions, and no significant differences between wild-type
and Il22-/- mice (Figure 7b). However, we found that the lesions of Il22-/- mice had
higher expression of Il1a and Il1b compared with wild-type mice (Figure 7c). The
expression of these molecules is often observed in inflamed tissue and can be
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induced and released when cells encounter tissue damage (Carta, Lavieri,
Rubartelli 2013). Although there were no differences in the immune response
between wild-type and Il22-/- mice, increased expression of these damageassociated molecules demonstrates that Il22-/- mice directly or indirectly regulate
their production during infection with L. major.
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2.5 Discussion
Our results uncover a previously unknown role for IL-22 during cutaneous
leishmaniasis. While a pathologic and inflammatory role for IL-22 has been
reported in other cutaneous diseases (Ma et al. 2008; Pantelyushin et al. 2012;
Van Belle et al. 2012), we found that IL-22 does not promote increased
inflammation during infection with Leishmania spp. Rather, Il22-/- mice exhibited
more tissue damage than wild-type mice when infected with L. major or L.
braziliensis, suggesting that IL-22 limits pathology when a threshold of
inflammation is reached during leishmaniasis.
Our results demonstrate that the production of IL-22 is dependent on the
presence of CD4+ T cells, which have previously been shown to produce IL-22
(Liang et al. 2006; Zheng et al. 2007). However, γδ T cells, NK cells, ILCs and
neutrophils are other potential sources of IL-22 that might contribute to the IL-22
observed in these lesions (Carlsen et al. 2015; Taube et al. 2011; Van Belle et al.
2012; Xu et al. 2014). Interestingly, the production of IL-22 appeared to be dosedependent, such that mice infected with higher doses of L. major expressed
higher levels of IL-22 in the lesions. Inflammation and damage in other models of
disease have been shown to induce IL-22 expression (Aujla and Kolls 2009;
Sonnenberg et al. 2010; Zenewicz et al. 2008; Zheng et al. 2007; Zheng et al.
2008), consistent with our findings that higher doses of L. major elicit more
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Figure 7: IL-22 does not alter the immune response during L. major infection. Wild-type and
-/6
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inflammation and higher expression of IL-22. Conversely, we observed a
decrease in the expression of the IL-22 antagonist, IL-22BP, in mice with higher
doses of the parasite. This inverse relationship of IL-22/IL-22BP regulating tissue
damage has also been observed during Hepatitis C and schistosome infections
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(Sertorio et al. 2015). Thus, we hypothesize that having a high IL-22/IL-22BP
ratio is required to limit pathology.In order to determine whether the immune
response was influenced by the absence of IL-22, we assessed cytokine
responses within leishmanial lesions of Il22-/- mice. Changes in the balance of
Th1 and Th2 cytokines is often associated with increased susceptibility to L.
major, but since there were no differences in the parasite burden it was not
surprising that the mRNA levels of Ifng, Tnfa, Il12p40 and Il4 were similar in both
wild-type and Il22-/- mice. Moreover, there were no differences in the cellular
infiltrate of T cells and myeloid cells in the lesions of wild-type and Il22-/- mice.
These results prompted us to consider other ways in which IL-22 can provide
tissue protection during inflammation.
L. major infection leads to the development of ulcerated lesions that
eventually resolve due to tissue remodeling at the infection site (Baldwin et al.
2007; Elso et al. 2004a; Elso et al. 2004b). IL-22 promotes wound healing by
increasing epithelial cell proliferation, decreasing the differentiation of
keratinocytes and inducing anti-apoptotic molecules in keratinocytes (Boniface et
al. 2005; Radaeva et al. 2004; Vogl et al. 2004; Wolk et al. 2006). Thus, one way
IL-22 may enhance wound healing in leishmaniasis is by regulating L. major
induced keratinocyte death. Additionally, IL-22 stimulates fibroblasts to produce
extracellular matrix proteins, as well as increases the differentiation of
myofibroblasts that help to contract wounds (McGee et al. 2013), and both of
these functions could be critical in the resolution of leishmanial lesions. In this
study, we found another mechanism in which IL-22 contributes to wound healing
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and tissue repair. Keratinocyte proliferation and differentiation are critically
regulated processes during wound repair (Martin 1997). Upon injury, activated
keratinocytes migrate to close the wound, while basal keratinocytes proliferate at
the basement membrane (Usui et al. 2005; Usui et al. 2008). In order for a cell to
proliferate and repair the basement membrane, differentiation must be halted
(Usui et al. 2005). IL-22 can induce proliferation, but also down-regulate
keratinocyte differentiation and keratin expression (Boniface et al. 2005). Thus,
we decided to examine the expression of various proliferation and differentiation
markers. While the proliferation markers, keratin 5 and keratin 14 were
unaffected by the absence of IL-22, the lesions of Il22-/- mice expressed higher
levels of keratins 6a and 16. These genes are induced in keratinocytes upon
injury and are maintained during reepithiliazation. However, the intensity in
expression levels of these keratins is important because their overexpression can
lead to defects in keratinocyte migration and wound closure (Wawersik et al.
2001). The higher expression of keratins 6a and 16 observed in chronic wounds
is consistent with our data showing that Il22-/- mice have a defect in wound repair
during L. major infection. Interestingly, lower expression of keratin 16 or deletion
of keratin 6a can enhance keratinocyte migration (Rotty and Coulombe 2012),
which may explain the eventual lesion resolution in wild-type mice with lower
expression of these keratins. Keratinocyte differentiation and migration are key to
wound healing, and thus our results suggest that IL-22 may be important in
regulating these processes through keratins 6a and 16 in order to efficiently
resolve leishmanial lesions.
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While IL-22 protects against certain pathogens, such as Klebsiella
pneumonia and Citrobacter rodentium (Aujla et al. 2008; Zheng et al. 2008), in
our study we found no evidence that IL-22 contributes to control of L. major or L.
braziliensis, as wild-type and Il22-/- mice contained the same number of parasites
in their lesions. These results are similar to those observed with other parasites,
such as Toxoplasma gondii or Schistosoma mansoni (Wilson et al. 2010).
However, this is in contrast to visceral leishmaniasis, where the production of IL22 has been correlated with increased protection (Ghosh et al. 2013; Pitta et al.
2009). How IL-22 promotes resistance in visceral leishmaniasis is unknown, but it
is unlikely to be a direct effect on the parasites, since the IL-22R is not expressed
on the cells infected with leishmania (Wolk et al. 2004). Since stromal cells play a
role in immunoregulation in visceral leishmaniasis, one possibility is that
stimulation of stromal cells by IL-22 might indirectly influence the development of
disease (Svensson et al. 2004).
IL-22 helps maintain barrier function in the skin, but when produced at
high levels and/or in the context of other proinflammatory cytokines, such as IL17, IL-22 promotes increased pathology (Sonnenberg et al. 2010). The factors
that determine whether IL-22 will play a protective or pathologic role remain
poorly understood, although it has been suggested that the nature of the
inflammatory response may be a determining factor (Sonnenberg et al. 2010).
Our results indicate that one factor determining whether IL-22 is important in
protection in the skin may be the degree of damage induced. Thus, when Il22-/mice were infected with a high dose of parasites, we routinely saw increased
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pathology in Il22-/- mice compared with wild-type mice, while we found no
differences in the development of lesions in Il22-/- mice and wild-type mice when
the animals were infected with a low dose of parasites. The latter finding would
account for the results of a prior study where IL-22 was reported to have no role
in L. major infection (Brosch et al. 2014). These results suggest that the
protective role for IL-22 requires a threshold of inflammation that is reached at
high parasite doses in this experimental model. This raises the issue of how our
murine studies relate to human leishmaniasis. While the initial dose of parasites
transmitted by sandflies is much less than the high doses we have studied here,
patients also exhibit significantly more pathology than what occurs in low dose
infections in mice. Thus, we hypothesize that in more severe forms of cutaneous
leishmaniasis, as often seen following L. braziliensis infection, IL-22 might be
induced to ensure that even more severe disease does not develop. Consistent
with this was our finding that cells from patients made IL-22 in response to
stimulation, indicating that there was sufficient damage in the patients to promote
IL-22 production.
Taken together, our results in Il22-/- mice show that IL-22 limits pathology
during cutaneous leishmaniasis and suggest that once a certain threshold of
damage is reached, IL-22 is expressed at higher levels and limits subsequent
damage by maintaining skin barrier integrity and wound healing capacities. In the
absence of IL-22, not only do lesions fail to resolve, but higher expression of the
inflammatory molecules IL-1α and IL-1β may lead to even greater tissue
destruction. Thus, IL-22 plays an important, and previously unappreciated, role in
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maintaining skin repair properties and limiting inflammation during cutaneous
leishmanial infections.
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CHAPTER 3: CUTANEOUS LEISHMANIASIS INDUCES A TRANSMISSIBLE
DYSBIOTIC SKIN MICROBIOTA THAT PROMOTES SKIN INFLAMMATION
3.1 Abstract
Skin microbiota can impact allergic and autoimmune responses, wound
healing and defense against pathogens. Here, we investigated their role in
cutaneous leishmaniasis. We found that infection with leishmania altered the skin
microbiota at the lesion site, characterized by increases in the abundance of
Staphylococcus, Streptococcus, or both. When we infected mice with leishmania
we observed similar changes depending upon disease severity. Unexpectedly,
the dysbiosis was not limited to the lesion site, but was transmissible to skin
distant from the infection site, and to skin from co-housed naïve mice. This
observation allowed us to test whether a pre-existing dysbiotic skin microbiota
influences disease. We found that dysbiotic naïve mice challenged with L. major
or tested for contact hypersensitivity had exacerbated skin inflammatory
responses. These findings demonstrate that a dysbiotic skin microbiota is not
only a consequence of skin injury, but also enhances inflammation, which has
implications for many inflammatory cutaneous diseases.
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3.2 Introduction

The skin is a barrier and the body’s first line of defense against injury and
infection. It also hosts commensal populations of bacteria, fungi and viruses that
may influence wound healing, the immune response to infection, and
inflammatory responses that occur in chronic diseases(Canesso et al. 2014;
Grice et al. 2010; Naik et al. 2012). Though there are strong associations
between certain human diseases and changes in the skin microbiota(Kong et al.
2012; Loesche et al. 2016; Oh et al. 2013), the consequences of such changes
are unclear, including the role of skin commensal microbes in modulating dermal
cellular responses. Animal models in which microbial communities can be
manipulated are essential to determine whether these changes influence the
outcome of disease.
Cutaneous leishmaniasis is caused by intracellular protozoan parasites
and is characterized by a spectrum of clinical manifestations, ranging from selfhealing single lesions to chronic, and in some cases metastatic, lesions(Scott
and Novais 2016). The factors responsible for chronic disease in leishmaniasis
are still being defined, although it is clear that some of the most severe forms of
the disease are not caused by uncontrolled parasite replication, but rather an
exaggerated immune response leading to excessive inflammation(Antonelli et al.
2005; Lopez Kostka et al. 2009; Santos Cda et al. 2013; Gonzalez-Lombana et
al. 2013; Novais et al. 2013; Crosby et al. 2014). Unfortunately, there is no
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vaccine for leishmaniasis and drug treatment is often ineffective, which provides
the impetus for better understanding the factors that drive the destructive
inflammatory responses. Some of these severe forms of disease can be
mimicked in mice, which can develop healing or non-healing disease following L.
major infection depending upon whether a dominant Th1 or Th2 response
develops (Scott and Novais 2016). Less well understood is the role the skin
microbiota plays in cutaneous leishmaniasis. Although it has been reported that
the course of infection in germ free mice differs from conventional mice (de
Oliveira et al. 1999; Naik et al. 2012; Oliveira et al. 2005), how the skin
microbiota changes in patients and conventional mice, and whether such
changes influence disease is less clear.
In this study, we found that infection with leishmania parasites causes a
decrease in bacterial diversity in the skin that is characterized by communities
dominated by Staphylococcus spp. and/or Streptococcus spp in both humans
and mice. We hypothesized that disease-associated shifts in the skin microbiota
(“dysbiosis”) contribute to lesion pathology and dermal cellular responses,
including immune and inflammatory responses in L. major infection. To test this
we utilized a mouse model of cutaneous leishmaniasis, and found that infection
with L. major changed the skin microbiota in a manner dependent on disease
severity. Leishmania-induced dysbiosis was not confined to the site of infection,
but occurred globally on the skin of infected mice, and moreover, was transferred
to uninfected co-housed mice. Colonization of skin with Staphylococcus xylosus
isolated from the dysbiotic mice increased inflammatory responses in a contact
54

hypersensitivity model, although not in normal skin, indicating that dysbiosis
might exacerbate disease. Dysbiotic microbiota, when transferred to naïve mice
prior to leishmania infection, increased disease pathology compared to control
animals. Taken together these results indicate that the skin microbiota influences
the inflammatory response in leishmaniasis and other inflammatory skin
conditions. This work has significant implications for the treatment of cutaneous
leishmaniasis and other skin diseases, and highlights the potential of the skin
microbiota as a therapeutic target.
3.3 Materials and methods
Experimental model and subject details
Mice
Female C57BL/6 and BALB/c mice 6-8 weeks old were purchased from the
Charles River Laboratories (Durham, NC). All mice were maintained in specific
pathogen-free facilities at the University of Pennsylvania. Cages were changed
twice per week with glove changes between handling each cage. Unless stated
otherwise, a minimum of 5 mice were used based on variability observed in
previous experiments with L. major. Mice were randomly assigned to
experimental groups by investigators. Investigators were not blinded in this study.
Prior to infection, mice were anesthetized using a ketamine and xylazine mixture
and monitored until the mice were fully awake. At the end of the experiments,
mice were humanely euthanized using carbon dioxide inhalation. All procedures
involving mice were performed in accordance with the guidelines of the
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University of Pennsylvania Institutional Animal Care and Use Committee
(IACUC).

Human Cutaneous Leishmaniasis Subjects
All cutaneous leishmaniasis patients were seen at the health post in Corte de
Pedra, Bahia, Brazil, which is a well-known area of L. braziliensis transmission.
The criteria for diagnosis were a clinical picture characteristic of cutaneous
leishmaniasis in conjunction with documentation of DNA of L. braziliensis by
PCR, or parasite isolation or documentation of amastigotes in lesion biopsies by
histopathology. In all cases, swabs were collected before therapy. There were 44
patients, both male (72.7%) and female (27.3%), with a median age of 27 years.
This study was conducted according to the principles specified in the Declaration
of Helsinki and under local ethical guidelines (Ethical Committee of the
Maternidade Climerio de Oliveira, Salvador, Bahia, Brazil; and the University of
Pennsylvania Institutional Review Board). This study was approved by the
Ethical Committee of the Federal University of Bahia (Salvador, Bahia,
Brazil)(010/10) and the University of Pennsylvania IRB (Philadelphia,
PA)(813390). All patients provided written informed consent for the collection of
samples and subsequent analysis.

Parasite and Bacterial Cultures
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L. major (WHO/MHOM/IL/80/Friedlin wild-type L. major) promastigotes were
grown to the stationary phase in Schneider’s Drosophila medium (GIBCO BRL,
Grand Island, NY, USA) supplemented with 20% heat-inactivated fetal bovine
serum (FBS, Invitrogen USA), 2 mM L-glutamine, 100 U of penicillin and 100 µg
of streptomycin per mL. Infective-stage promastigotes (metacyclics) were
isolated from 4-5 day old (L. major)
Mice
Female C57BL/6 and BALB/c mice 6-8 weeks old were purchased from the
Charles River Laboratories (Durham, NC). All mice were maintained in specific
pathogen-free facilities at the University of Pennsylvania. Cages were changed
twice per week with glove changes between handling each cage. Unless stated
otherwise, a minimum of 5 mice were used based on variability observed in
previous experiments with L. major. Mice were randomly assigned to
experimental groups by investigators. Investigators were not blinded in this study.
Prior to infection, mice were anesthetized using a ketamine and xylazine mixture
and monitored until the mice were fully awake. At the end of the experiments,
mice were humanely euthanized using carbon dioxide inhalation. All procedures
involving mice were performed in accordance with the guidelines of the
University of Pennsylvania Institutional Animal Care and Use Committee
(IACUC).
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Pennsylvania Institutional Review Board). This study was approved by the
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samples and subsequent analysis.

Parasite and Bacterial Cultures
L. major (WHO/MHOM/IL/80/Friedlin wild-type L. major) promastigotes were
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Grand Island, NY, USA) supplemented with 20% heat-inactivated fetal bovine
serum (FBS, Invitrogen USA), 2 mM L-glutamine, 100 U of penicillin and 100 µg
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of streptomycin per mL. Infective-stage promastigotes (metacyclics) were
isolated from 4-5 day old (L. major) stationary culture by density gradient
separation by Ficoll (Sigma) (Spath and Beverley 2001). An isolate of S. xylosus
and alpha-hemolytic Streptococcus was cultured from the ears of L. major
infected mice. For topical associations and infections, the bacteria was cultured
in Brain heart infusion (BHI) media (Remel, Lenexa, KS, USA) shaking for 12
hours at 37°C.

Method details

Leishmania infection and in vivo antibody depletions
Mice were inoculated intradermally in the ear with 10 µL of PBS containing 2 x
106 L. major metacyclic promastigotes. Lesion development was measured
weekly by ear thickness with a digital caliper (Fisher Scientific). Mice were also
assessed for pathology, using the following score system: no lesion (0),
swelling/redness (1), deformation of the ear pinna (2), ulceration (3), partial
tissue loss (4), and total tissue loss (5). Parasite burden in lesion tissues was
assessed using a limiting dilution assay as previously described (Zaph et al.
2004). In specified experiments, mice were treated with 500µg of anti-IL-12 mAb
(BioXcell, clone R1-5D9) one day prior to infection and then twice per week for
the duration of the experiment. Equal amounts of an isotype control, Rat IgG2a
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(BioXcell, clone 2A3) was given in all experiments using in vivo antibody
treatments.

Bacterial topical associations, intradermal infections, and CFU
quantification
For topical associations,108-109 CFUs of bacteria were applied to the entire
mouse body using sterile cotton swabs, every other day for a total of 4 times. For
intradermal infections, mice were inoculated with 10µL of 108-109 CFU
bacteria/mL culture. For CFU quantification, the dermal sheets of the mouse ears
were homogenized in 1mL of PBS using a tissue homogenizer (FastPrep-24, MP
Biomedical) and plated on tryptic soy blood agar (Remel) or mannitol salt agar
(Acumedia) in serial dilutions. Plates were incubated overnight at 37°C and CFUs
were counted the next day.

Contact hypersensitivity and antibody treatments
For sensitization, 1-fluoro-2,4-dinitrobenzene (DNFB) (Sigma-Aldrich) was added
to a 3:1 acetone:olive oil dissolvent to get a final concentration of 0.5%. Mice
were treated on the belly with 30µL of the mixture. During the challenge phase,
mice were treated with 20µL of 0.3% DNFB (in 3:1 acetone:olive oil) on the ear
once a day, for a total of 3 days. The mice were euthanized 24 hours after the
last challenge. In some experiments, mice were treated with 500µg of a Rat
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IgG2a isotype monoclonal antibody (BioXcell, clone 2A3), an anti-mouse IL-17A
monoclonal antibody (BioXcell, clone 17F3), or an anti-mouse IL-1R monoclonal
antibody (BioXcell, clone JAMA-147), one day prior and one day after the first
challenge with DNFB.

Preparation of dermal sheets
The dorsal and ventral sides of the mouse ear were split mechanically and
placed dermis side down in a 24 wells plate in RPMI 1640 containing 0.25 mg/mL
of Liberase TL (Roche, Diagnostics Corp.) and 10 mg/mL DNase I (SigmaAldrich). Ears were incubated for 90 min at 37° C in a 24-well plate. Dermal cell
suspensions were prepared by dissociation on 40 µm cell strainer (Falcon) in
PBS containing 0.05% BSA and 20 mM EDTA.

Antibodies and flow cytometry
Single cell suspensions from the ear were obtained as described above. For
analysis of surface markers and intracellular cytokines, some cells were
incubated for 4 h with 10 mg/mL of brefeldin A, 50 ng/mL of PMA and 500 ng/mL
ionomycin (Sigma-Aldrich). Before staining, cells were incubated with antimouse CD16/CD32 mouse Fc block (eBioscience) and 10% rat-IgG in PBS
containing 0.1% BSA. Cells were stained for dead cells with LIVE/DEAD Fixable
Aqua Dead Cell Stain Kit (Molecular Probes) and surface markers (CD4
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[eBioscience, clone RM4-5], CD8b [BioLegend, clone YTS156.7.7], CD45
[eBioscience, clone 30-F11], Ly6G [eBioscience, clone 1A8-Ly6g], CD11b
[eBioscience, clone M1/70]) followed by fixation with 2% of formaldehyde and
permeablization with 0.2% saponin/PBS. Intracellular cytokine staining was
performed for pro-IL-1β (eBioscience, clone NJTEN3). The data were collected
using LSRII flow cytometer (BD) and analyzed using FlowJo software (Tree
Star).

RNA isolation, purification, and quantitative real-time PCR.
Total RNA was extracted from ear tissue samples in 500µL of RLT lysis buffer
(QIAgen). The sample was homogenized using a tissue homogenizer (FastPrep24, MP Biomedical), and total RNA was extracted according to the
recommendations of the manufacturer and further purified using the RNeasy Mini
kit (QIAgen). RNA was reverse transcribed using high capacity RNA-to-cDNA Kit
(Applied Biosystems). Real-time RT-PCR was performed on a ViiA™ 7 RealTime PCR System (Applied Biosystems). Relative quantities of mRNA for several
genes were determined using SYBR Green PCR Master Mix (Applied
Biosystems) and by the comparative threshold cycle method, as described by the
manufacturer. mRNA levels for each sample were normalized to the ribosomal
protein S11 gene (RPS11). The primer sequences were as follows: Rps11,
forward, 5’-CGTGACGAAGATGAAGATGC-3’ and reverse, 5’GCACATTGAATCGCACAGTC-3’; Il17, forward, 5'62

CATGAGTCCAGGGAGAGCTT-3' and reverse, 5'GCTGAGCTTTGAGGGATGAT-3'; Tnfa, forward, 5'TCACTGGAGCCTCGAATGTC-3' and reverse, 5'GTGAGGAAGGCTGTGCATTG-3'; Il1b, forward, 5’TTGACGGACCCCAAAAGAT-3’ and reverse, 5’- GATGTGCTGCTGCGAGATT3’; Cxcl1, forward, 5'-GCACCCAAACCGAAGTCATA-3' and reverse, 5'CTTGGGGACACCTTTTAGCA-3'; and Ccl2, forward, 5’GCTTCTGGGCCTGCTGTTCA-3’ and reverse, 5’AGCTCTCCAGCCTACTCATT-3’.

Microbiota collection, sequencing, and analysis
Microbiota samples were collected from the ear of mice using a swab (Catch-all
Sample Collection Swab, Epicentre) moistened in Yeast Cell Lysis Buffer (from
MasterPure Yeast DNA Purification Kit; Epicentre). DNA was isolated from swab
specimens using the PureLink Genomic DNA Mini Kit (Invitrogen) and
amplification of the 16S-V4 region for the murine samples, and 16S-V1-V3 region
for the human samples, was performed as previously described (Hannigan et al.
2014; Meisel et al. 2016). Sequencing of 16S rRNA amplicons was performed at
the Penn Next Generation Sequencing Core using the Illumina MiSeq platform
with 150 bp paired-end ‘V4’ chemistry for murine samples and with 300 bp
paired-end ‘V1-V3’ chemistry for the human samples. For the fecal samples,
DNA was isolated using the PowerSoil DNA Isolation Kit (Mo Bio) and
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sequencing of the 16S rRNA amplicons was conducted using 250bp paired-end
‘V4’ chemistry with dual index primers (Kozich et al. 2013).

QUANTIFICATION AND STATISTICAL ANALYSIS

Pre-processing and community characterization of 16S rRNA sequence
data
Sequence pre-processing followed methods previously described (Hannigan et
al. 2014), but modified by subsampling at 5000 sequences per sample for murine
samples, and at 1000 sequences per sample for human samples. QIIME
1.8.0(Caporaso et al. 2010) was used for initial stages of sequence analysis.
Sequences were clustered into OTUs (operational taxonomic units, a proxy for
‘species’) using UCLUST(Edgar 2010) at 97% sequence similarity. Bacterial
diversity was calculated using the following alpha diversity indices: Shannon
diversity index and the number of observed OTUs. Relative abundance of
bacteria was calculated based on taxonomic classification of sequences using
the RDP classifier (Wang et al. 2007) at a confidence threshold of 0.8. Microbiota
data was analyzed with the R statistical software environment (ww.r-project.org).
Statistical significance was determined using two-sample Wilcoxon tests and
corrected for multiple comparisons by FDR where appropriate. Dirichlet

64

multinomial mixture modeling was performed using the R package Dirichlet
Multinomial and calculated as previously reported (Loesche et al. 2016).

Statistical analysis
Results represent means ± SEM. Data were analyzed using Prism 7.0
(GraphPad Software, San Diego, CA). Statistical significance was determined by
one-way ANOVA when comparing more than two groups and by an unpaired
two-tailed Student’s t test to compare means of lesion sizes, parasite burdens,
and cytokine production from different groups of mice. Variances were equal
between experimental groups. Statistically significant differences were defined as
* when p values were <0.05.
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3.4 Results

Characterization of microbiota colonizing human leishmaniasis lesions and
skin
Dysbiosis in skin microbiota is often associated with inflammation and
disease (Grice et al. 2010; Kobayashi et al. 2015; Kong et al. 2012; Oh et al.
2013), suggesting that cutaneous lesions in leishmaniasis might also exhibit
changes in the skin-residing bacterial communities. To test this, we analyzed the
microbiota of 44 patients infected with L. braziliensis (72.7% male, 27.3% female,
median age, 27 years old), with lesions present at various body sites (Table 1).
We collected 2-3 skin swabs for each patient including the lesion, adjacent skin
near the lesion, and unaffected contralateral skin of the same body site as the
lesion (Figure 8A). Bacterial diversity was significantly lower in lesions compared
to unaffected contralateral skin and adjacent skin sites, as measured by the
observed species-level operational taxonomic units (OTUs) and Shannon
Diversity indices (Figure 8B).
Interestingly, the skin microbiota on the adjacent skin sites appeared more
similar in composition to the lesions than to the contralateral skin (Figure 9a). To
quantify the similarity between each site where specimens were collected, we
used the Bray Curtis dissimilarity metric of shared microbial community structure.
We observed that lesion and adjacent skin shared greater microbial community
structure compared to contralateral and adjacent skin (Figure 8C). This data
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suggests that microbiota colonizing the lesion is shared with adjacent skin sites,
which may have implications in the immune responses at those sites.
We then applied a Dirichlet multinomial mixture model-based approach to
assign the lesions to different community types (CTs) based on their taxonomic
composition. Lesions clustered into 3 CTs (Figure 8D and Figure 9B) with distinct
bacterial compositions. The top discriminating taxa in CT1 was Staphylococcus
aureus, CT2 displayed a heterogeneous composition with no dominating taxa,
and CT3 was dominated by an unclassified species of Streptococcus (Figure 8E
and Table 2). These results suggest that cutaneous leishmaniasis lesions are
colonized with microbiota similar to other cutaneous ulcers (Kong et al. 2012; Oh
et al. 2013; Loesche et al. 2016), but display less heterogeneity of the colonizing
microbiota, which is driven primarily by proportions of Staphylococcus aureus
and Streptococcus spp. in this cohort. Interestingly, neither bacteria were
associated with larger lesion sizes (Figure 9C), but lesion size may not be a good
predictor of disease severity or outcome. Additional epidemiologic studies may
be needed to further evaluate the influence of the skin microbiota in cutaneous
leishmaniasis, yet these results clearly demonstrate that infection with leishmania
alters the skin microbiota, creating several types of dysbiosis.
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Supplemental Table 1
Subject ID
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

Sex
Male
Male
Male
Male
Male
Male
Female
Male
Male
Male
Female
Female
Male
Female
Male
Male
Female
Male
Female
Male
Female
Male
Female
Male
Male
Male
Male
Male
Female
Male
Male
Male
Male
Male
Male
Male
Female
Male
Male
Female
Female
Female
Male
Male

Age
22
43
18
24
20
16
30
36
31
22
24
39
22
45
26
21
33
21
20
29
35
37
26
25
50
55
18
19
24
40
57
18
19
28
39
31
24
63
20
16
24
64
33
59

Body Site
Leg
Neck
Ankle
Leg
Leg
Back
Leg
Thigh
Face
Arm
Thigh
Leg
Leg
Leg
Leg
Arm
Leg
Leg
Leg
Leg
Leg
Foot
Arm
Leg
Leg
NA
Head
Leg
Abdomen
Leg
Leg
Leg
Foot
Leg
Leg
Leg
Leg
Leg
Arm
Chest
Back
Leg
Abdomen
Thigh

Lesion Size (mm2)
396
216
NA
225
660
500
544
437
840
49
25
70
3300
180
90
200
380
780
80
500
100
24
130
150
270
1575
192
480
325
130
35
49
306
25
77
330
1476
272
1377
30
255
216
207
340

Duration of Lesion (Days)
30
30
40
40
90
30
21
30
60
30
30
30
40
30
10
60
40
21
30
60
60
60
30
21
30
60
34
14
NA
20
45
20
15
15
30
90
60
20
45
20
30
30
40
90

Skin Test (mm2)
440
225
300
144
725
440
225
Negative
300
400
210
130
110
378
260
400
NA
228
100
180
255
300
285
180
272
1085
130
208
700
460
132
400
441
49
255
130
625
196
225
156
144
NA
289
255

Table 1: Information about samples collected from cutaneous leishmaniasis patients.
Swabs were collected from these cutaneous leishmaniasis patients prior to treatment. All
cutaneous leishmaniasis patients were seen at the health post in Corte de Pedra, Bahia, Brazil,
which is a well-known area of L. braziliensis transmission. The criteria for diagnosis were a
clinical picture characteristic of cutaneous leishmaniasis in conjunction with parasite isolation or a
positive delayed-type hypersensitivity response to Leishmania antigen, plus histological features
of cutaneous leishmaniasis.
.
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Figure 8: Lesions from cutaneous leishmaniasis patients also have a dysbiotic skin
microbiota. (A) Swabs were collected from the lesion, nearby adjacent skin, and contralateral
skin sites for 16S rRNA analysis. (B) Bacterial diversity was assessed by the number of observed
species-level OTUs and Shannon Index. (C) Bar charts represent intragroup mean Bray-Curtis
dissimilarity between each skin site. (D) PCoA values for weighted UniFrac analysis were plotted
and colored based on the Dirichilet multinomial cluster assignment. (E) Stacked bar charts
represent the proportion of the top 10 taxa present in each Dirichilet cluster. Samples were
collected from an n = 44 patients.
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Figure 9: Samples from all patients are diverse and Dirichilet multinomial clusters lesions
into 3 community types. (A) Stacked bar charts represent the proportion of the top 10 taxa
present in each sample. Patients are identified by number and skin type is identified as lesion (L),
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adjacent skin sites (A), or contralateral skin sites (C). (B) Laplace approximation was used to
measure the model fit of the Dirichilet multinomial mixture analysis. The lowest value (3) indicates
the best fit for the model. (C) PCoA values for weighted UniFrac analysis were plotted and
colored based on the ratio of the abundances of Staphylococcus spp. to Streptococcus spp. in
each lesions sample and circle size is based on size of the lesion of each sample.

Supplemental Table 2
Taxa

Cluster 1

Cluster 2

Cluster 3

Staphylococcus aureus
Unclassified Streptococcus
Unclassified Bacilli
Unclassified Gemellales
Unclassified Staphylococcus
Bacillus flexus
Unclassified Staphylococcus
Unclassified Streptococcus
Unclassified Bacillales
Staphylococcus epidermidis

0.788992731
0.022511662
0.04901982
0.030965307
0.013819064
0.002613152
0.010710605
0.007199348
0.002463076
0.001303855

0.16077901
0.11087683
0.10691883
0.06667456
0.06478127
0.06594624
0.02253503
0.0130796
0.02473744
0.02767135

0.049802691
0.814618671
0.018451401
0.013448359
0.005975455
0.00479366
0.004936899
0.01322084
0.001617316
0.001574108

Table 2: Top 10 discriminating taxa that make up the Dirichilet multinomial clusters.
Dirichlet multinomial mixture model-based approach was used to assign the lesions into different
clusters based on their taxonomic composition. This tables provides a list of the top 10
discriminating taxa that make up each cluster and their proportional contribution to the cluster.

L. major infection induces changes to the skin microbiota in mouse models
Since the influence on disease of a dysbiosis is difficult to evaluate in
humans, we employed a mouse model of leishmaniasis to assess the role
dysbiosis might play in cutaneous leishmaniasis. C57BL/6 mice were infected in
the ear with L. major parasites, which led to the development of a lesion that
resolved by 12 weeks post-infection (Figure 10A-B). Prior to infection, and at 6
and 12 weeks post-infection, swabs were collected from the ventral and dorsal
ear skin and sequencing of the 16S ribosomal RNA gene was employed to
assess skin microbial diversity and composition. Alpha diversity, as measured by
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the number of observed species-level OTUs and Shannon Diversity indices,
decreased at 6 weeks post-infection, but returned to pre-infection levels upon
lesion resolution (Figure 10C-D). This shift in alpha diversity was paralleled by a
significant increase in the relative abundance of Staphylococcus spp. after lesion
development that returned to pre-infection levels once the lesions resolved
(Figure 10E). MALDI-Tof mass spectrometry identified the Staphylococcus
species associated with L. major infection as S. xylosus (data not shown), a
common commensal bacteria found on mouse skin (Nagase et al. 2002). Since
infections can often lead to changes in the intestinal microbiota (Kamdar et al.
2016; Lozupone et al. 2013), we also analyzed the fecal microbiota of infected
mice, but found no significant changes in the fecal bacterial populations
throughout the course of infection with L. major (Figure 10F), demonstrating that
dysbiosis caused by infection is localized to the skin.

L. major induced dysbiosis differs depending on the severity of the disease
Inflammatory responses induced by a variety of skin insults lead to
changes in the skin microbiota (Grice et al. 2010; Gontcharova et al. 2010; Kong
et al. 2012; Oh et al. 2013; Loesche et al. 2016), but whether the magnitude of
the insult alters the nature or degree of the dysbiosis is not known. To address
this we compared the microbiota from L. major infected C57BL/6 mice that
resolve their infection and BALB/c mice that develop severely ulcerated nonhealing lesions (Figure 11A-B) (Scott and Novais 2016). Similar to C57BL/6
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mice, BALB/c mice had significantly lower alpha diversity at 6 weeks postinfection (Figure 11C). However, in contrast to the dominance of Staphylococcus
spp. found on lesions of C57BL/6 mice, BALB/c mice had a dominance of
Streptococcus spp. at 6 weeks post-infection, (Figure 11D). To rule out the
possibility that the increase in Streptococcus in non-healing BALB/c mice was
due to differences in the mouse strain, we depleted IL-12 in C57BL/6 mice, which
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Figure 10: L. major infection alters the skin microbiota. C57BL/6 mice were intradermally
6
infected in the ear with 2 x 10 L. major parasites. (A) Lesion size and (B) pathology were
assessed over 12 weeks of infection. Swabs were collected from the ear at 0, 6, and 12 weeks
post-infection and bacterial diversity was assessed by (C) number of observed species-level
OTUs and (D) Shannon Index. Stacked bar charts represent the proportion of the top 10 taxa
present (E) from ear swabs and (F) from fecal pellets at 0, 6, and 12 weeks post-infection. Each
column represents the proportion of taxa for an individual mouse. Data represent two
independent experiments (For skin swabs, n = 15 mice and for fecal pellets, n =10 mice).
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leads to non-healing lesions similar to those seen in BALB/c mice(Heinzel et al.
1989; Scharton-Kersten et al. 1995). As expected, anti-IL-12 mAb treated mice
developed large non-healing lesions (Figure 11E-F). At 4 weeks post-infection
Staphylococcus spp. made up a high proportion of the skin microbiota in both
groups of mice (Figure 11G). However, while the relative abundance of
Streptococcus spp. remained less than 1% of the total population in control mice,
it increased significantly in anti-IL-12 treated mice to >50% relative abundance
(Figure 11G), further demonstrating that Streptococcus spp. are associated with
more severely ulcerated lesions. Taken together, our data suggest that L. major
infection elicits severity-dependent changes in the skin microbiota.

S. xylosus mediated inflammation is dependent on skin barrier integrity
To determine if the dysbiosis caused by L. major infection would influence
skin inflammatory responses, we topically associated naïve mice with S. xylosus
(Figure 12A). One week following colonization with S. xylosus mice exhibited a
significantly higher relative and absolute abundance of Staphylococcus spp.
compared with naïve mice by culture-independent (Figure 12B) and culturedependent assays (Figure 12C). CD4+ T cells, CD8+ T cells, CD11b+ myeloid
cells (Figure 12D), and cytokine production (data not shown) were unchanged in
skin colonized with S. xylosus compared to naïve skin. To determine if S. xylosus
incites inflammation upon breach of the skin barrier, we injected mice
intradermally with S. xylosus and analyzed the inflammatory response in the skin.
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Figure 11: Skin microbiota alterations in L. major infection are dependent on disease
severity. C57BL/6 and BALB/c mice were intradermally infected with L. major parasites. Lesional
severity was assessed by (A) ear thickness and (B) a pathology score over the course of
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infection. Swabs for sequencing of 16S rRNA genes were collected from the lesions at 0 and 6
weeks post-infection. (C) Alpha diversity was assessed by Shannon Index. (D) Stacked bar
charts represent the proportion of the top 10 taxa present in each sample. Data are
representative of two independent experiments (n=5-10 mice per group). C57BL/6 mice were
treated with an isotype or anti-IL-12 mAb and intradermally infected in the ear with L. major
parasites. Lesional severity was assessed by (E) ear thickness and (F) a pathology score over
the course of infection. Anti-IL-12 mAb treated mice were euthanized at 6 weeks post-infection
due to severe disease. (G) Swabs were collected from the lesions at 4 and 6 weeks post-infection
and proportions of Staphylococcus and Streptococcus were assessed. Data are representative of
two independent experiments (n=10 mice/group).

These mice had significantly higher expression of Il17, Tnfa, Il1b, Cxcl1, and
Ccl2 compared with either naïve or colonized mice (Figure 12E-F), suggesting
that S. xylosus might contribute to skin inflammation when the skin barrier is
compromised.
While skin colonized with S. xylosus appeared immunologically normal,
based on the results above we hypothesized that the response to damage might
differ between normal and dysbiotic skin. We tested this idea using a model of
contact hypersensitivity in which sensitizing and challenging the skin with a
known skin irritant, dinitrofluorobenzene (DNFB), increases transepidermal water
loss, an indication of skin barrier dysfunction (Figure 13A). Naïve C57BL/6 mice
were colonized with S. xylosus prior to sensitization with DNFB (Figure 13B).
DNFB challenge resulted in a significant increase in neutrophils (CD11b+ Ly6G+)
and expression of pro-IL-1β from myeloid cells (Figure 13C-D). Since IL-17 and
IL-1 can both lead to an increase in neutrophil recruitment, we investigated
whether these cytokines played a role in the increase of neutrophils in S. xylosus
treated mice. Mice colonized with S. xylosus were treated with an isotype control
mAb, anti-IL-17A mAb, or anti-IL-1R mAb prior to DNFB challenge (Figure 13E),
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and neutralizing IL-17 or IL-1 decreased neutrophil recruitment (Figure 13F).
Thus, it appears that once the integrity of the skin is compromised a commensal
such as S. xylosus can induce IL-17 and IL-1 expression, leading to increased
inflammation.

4

6

8 10 12 14
Analysis

1

E
0.0020

Il17
**
***

0.0010

0.0000

ns

0.4
0.2
0.0

Naive Colonized

0.0015

0.0005

0.6

Frequency of
CD11b+ cells (%)

2

ns

0.010
0.008
0.006
0.004
0.002
0.000

Naive Colonized

Tnfa
**
*
ns

Relative Expression

3

0

Relative Expression

ns

4

Frequency of
CD8+ cells (%)

Frequency of
CD4+ cells (%)

5

Relative Expression

D

0.2
0.1
0.0

0.010

10

***

600
400
200
0

Naive Colonized

Naive

Colonized

ns

8
6
4
2
0

Naive Colonized

Il1b
*
**

0.008
0.006
0.004
0.002

800

ns

0.000

F
0.005
0.004

Cxcl1
**
**

0.003
0.002
0.001
0.000

ns

Ccl2
Relative Expression

2

C

****

Relative Expression

S. xylosus
0

0.3

CFUs (per ear)

B
Proportion of
Staphylococcus

A

0.015

*
0.010
0.005

Naive
Colonized
Intradermal

*

ns

0.000

Figure 12: Staphylococcus xylosus isolated from L. major lesions causes inflammation
8
9
only when injected intradermally. (A) C57BL/6 mice were topically colonized with 10 -10 S.
xylosus every other day for a total of 4 applications; naïve mice were unassociated. (B) Prior to
and 14 days post colonization, swabs were collected to analyze the proportion of Staphylococcus.
(C) Ear lysates from naïve and S. xylosus colonized mice were cultured on mannitol salt agar
plates and colony forming units were counted after overnight incubation at 37°C. (D) Flow
cytometry analysis was performed for CD4+, CD8+, and CD11b+ cells in the ears of naïve or
colonized mice 14 days post-association. Cells were pregated on live, singlet, CD45+ cells. Data
are representative of two independent experiments (n = 4 mice/group). C57BL/6 mice were
topically colonized or intradermally infected in the ear with S. xylosus. Fourteen days later, skin
was harvested and mRNA expression was assessed for (E) cytokine and (F) chemokine genes.
Data are representative of one experiment (n = 5 mice/group).

To determine if colonization with Streptococcus spp. might have a similar
effect, we isolated Streptococcus from L. major infected mice that had been
77

treated with anti-IL-12 mAb. The immune responses in mice sensitized and
challenged with DNFB colonized with Streptococcus was unchanged (Figure
14A). However, we were unable to achieve stable colonization with the
streptococcal isolate (Figure 14B), suggesting that this particular lesionassociated Streptococcus isolate requires additional as yet undefined nutrients or
other conditions to colonize normal skin.

L. major-induced dysbiosis is transmissible to uninfected skin
The observation that the lesional microbiota of human cutaneous leishmaniasis
extends to adjacent seemingly normal skin sites prompted us to ask if the same
was true in the mouse model of L. major infection. To answer this question, we
compared the bacterial composition at the lesion site (infected ear) and the
contralateral ear of infected mice. As expected, the infected ear was dominated
by Staphylococcus spp. at the peak of infection. Interestingly, the contralateral
ear also had a high proportion of Staphylococcus spp., despite the absence of
infection (Figure 15A). We also observed higher bacterial loads on the infected
and contralateral ears when compared to naïve skin (Figure 15B). These data
demonstrate that in the mouse model, the dysbiotic microbiota caused by L.
major infection is transmissible to the non-inflamed, contralateral ear.
A dysbiotic intestinal microbiota is often transmissible by simply cohousing mice (Elinav et al. 2011a; Zenewicz et al. 2013). Whether transmission
of the skin microbiota also occurs is less clear, although co-habiting families may
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share their skin microbiota(Song et al. 2013). To directly address this issue we
tested if naïve mice co-housed with L. major infected mice might acquire their
dysbiotic microbiota. C57BL/6 mice were infected with L. major and co-housed
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Figure 13: S. xylosus colonization exacerbates skin inflammation during contact
hypersensitivity. (A) C57BL/6 mice were sensitized with DNFB or vehicle control on the belly
and challenged with DNFB or vehicle 5 days later. Transepidermal water loss was measured on
ear skin of vehicle control and DNFB treated mice. (B) C57BL/6 mice were topically associated
8
9
with 10 -10 S. xylosus every other day for a total of 4 applications and control C57BL/6 mice
were left unassociated. The next day, control and S. xylosus associated mice were sensitized on
the belly with DNFB. 5 days later, control and S. xylosus associated mice were challenged with
DNFB. Representative flow cytometry plots and graphs depict the expression of (C) CD11b+
8
Ly6G+ cells and (D) CD11b+ IL-1β+ cells. (E) C57BL/6 mice were topically associated with 10 9
10 S. xylosus every other day for a total of 4 applications and then treated with isotype, anti-IL17, or anti-IL-1R mAbs prior to sensitization and challenge with DNFB. (F) Graphs depict the
expression of CD11b+ Ly6G+ cells in the skin of treated mice. All data are representative of two
independent experiments (n = 5 mice/group).
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Figure 14. Streptococcus does not colonize naïve skin and fails to exacerbate skin
inflammation during contact hypersensitivity. (A) C57BL/6 mice were topically associated
8
9
with 10 -10 of an alpha hemolytic streptococcal isolate or S. xylosus every other day for 4
applications and control C57BL/6 mice were left unassociated. The next day, all mice were
treated on the belly with DNFB. Five days later, control alpha hemolytic Streptococcus and S.
xylosus mice were challenged with DNFB. Bar graphs of skin cells depict the abundance of
CD11b+ Ly6G+ cells present in the ear. (B) Colony forming units were measured after skin
homogenates were cultured on tryptic soy blood agar plates overnight from the ears of control
and alpha hemolytic or S. xylosus associated mice. Data are representative of two independent
experiments (n = 5 mice/group).

with naïve mice for 6 weeks, while a group of control naïve mice were housed
separately. Similar to the infected and contralateral ears, the skin of the co80

housed naïve mice also acquired a high abundance of Staphylococcus spp.,
while the control naïve mice maintained a diverse population of bacteria (Figure
15C). Our data demonstrate that the dysbiotic skin microbiota caused by L. major
infection is transmissible to naïve mice and allows us to assess the
consequences of this acquisition in inflammatory responses occurring in the skin.
L. major-induced dysbiosis exacerbates disease during inflammation and
infection
While we and others have shown that colonizing mice with a single
organism at high levels can alter immune responses (Figure 13) (Naik et al.
2012; Naik et al. 2015), whether a naturally transmitted dysbiosis would alter
immune skin immune responses has not been tested. To assess this, we cohoused naïve mice with L. major infected mice for 6 weeks to create “naïve”
dysbiotic mice. Control mice were housed separately and never exposed to L.
major infected mice. We then compared the contact hypersensitivity responses of
both groups of mice to DNFB. Dysbiotic co-housed mice had significantly more
neutrophils and pro-IL-1β production in the skin than control mice (Figure 16A-B),
similar to mice colonized with high numbers of bacteria.
Taken together, our results suggested that mice with dysbiotic skin might
respond differently to infection with L. major when compared with normal mice.
To determine if this was the case, naïve mice were co-housed with L. major
infected mice for 6 weeks and then infected with L. major. At 5 weeks postinfection, we analyzed the inflammatory cells and cytokines in the lesions of
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Figure 15. L. major induced dysbiosis is transmissible to uninfected skin. (A) C57BL/6 mice
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Figure 16: Dysbiosis exacerbates inflammation during DNFB treatment and L. major
infection. Naïve C57BL/6 mice acquired dysbiotic microbiota after co-housing with L. major
infected mice for 6 weeks. Control and dysbiotic mice were then sensitized and challenged with
DNFB. Representative flow cytometry plots and graphs of skin cells depict the expression of (A)
CD11b+ Ly6G+ cells and (B) CD11b+ IL-1β+ cells. Control and dysbiotic mice were intradermally
infected with L. major parasites and the cells from the lesions were collected at 5 weeks postinfection. Representative flow cytometry plots and graphs of skin cells depict the expression of
(C) CD11b+ Ly6G+ cells and (D) CD11b+ IL-1β+ cells. (E) A pathology score was used to assess
disease severity over 5 weeks post-infection. (F) Representative ear skin sections stained with
hemotoxylin and eosin of L. major infected control and dysbiotic mice. (G) Parasite burdens were
assessed using a limiting dilution assay after 5 weeks post-infection. Data are representative of
two independent experiments (For dysbiotic mice, n = 4 mice; for control mice, n = 5).

control and dysbiotic mice. Similar to DNFB challenge, L. major infected skin had
significantly more neutrophils and IL-1β in dysbiotic mice compared to control
mice (Figure 16C-D). Furthermore, the dysbiotic mice had significantly greater
lesion severity, characterized by increased skin ulceration, than control mice
(Figure 16E-F) despite similar parasite burdens (Figure 16G). These findings
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demonstrate that the skin microbiota influences the magnitude of lesion severity
following infection with L. major.
3.5 Discussion
Interactions between the immune system and the microbiota can be either
beneficial or harmful, depending on the context (Gaboriau-Routhiau et al. 2009;
Naik et al. 2012; Atarashi et al. 2013; Naik et al. 2015; Kobayashi et al. 2015). In
our studies, we found that leishmania infections in humans and mice change the
composition of the skin microbiota. The nature of the changes in mice differed
depending on the severity of inflammation, with Staphylococcus spp. dominant in
moderate lesions and Streptococcus spp. increasing in more severe lesions in
mice infected with L. major. In humans, we found individuals with a dominance
of Staphylococcus aureus, Streptococcus spp., or a mixture of both, although
whether these distinct skin microbiota influences the outcome of disease is yet
unknown. However, our studies in mice clearly suggest that further studies in
patients are warranted.
Why dysbiosis occurs during cutaneous leishmaniasis, or in other
inflammatory conditions, is unknown. Innate defenses, such as antimicrobial
peptides (AMPs), can target certain bacteria and play a role in disrupting the
microbiota in the intestine and in the skin(Cogen et al. 2010; Dorschner et al.
2001; Natsuga, Cipolat, Watt 2016; Nizet et al. 2001; Salzman et al. 2010), and
may also be responsible for the dysbiosis caused by L. major infection. We found
that infection with L. major causes changes in AMP expression in the skin (data
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not shown), and mice deficient in a cathelicidin-type antimicrobial peptide
(CAMP) appear more susceptible to infection with L. amazonensis (Kulkarni et al.
2006). Whether this deficiency in CAMP causes changes in the skin microbiota
remains to be determined, but these results in addition to our own findings
suggest that AMPs in cutaneous leishmaniasis warrant further investigation. How
AMPs might promote these changes is unclear, but virulence factors can make
bacteria resistant to AMPs and both Staphylococcus spp. and Streptococcus
spp. express genes that protect them from AMP killing(Kristian et al. 2005;
Peschel et al. 1999; Peschel et al. 2001), potentially providing them with a
survival advantage during L. major infection.
One difficulty in studying the microbiota is assessing how changes in the
skin microbiota influence disease, since skin dysbiosis is the consequence of the
inflammatory response in the skin. While transmissibility of dysbiotic microbiota
has been demonstrated in the intestinal tract(Elinav et al. 2011a; Zenewicz et al.
2013), our data is the first to demonstrate transmissibility of the skin microbiota in
a murine model. In this study and previous studies, colonization with a single
bacterial species enhanced pathology(Naik et al. 2012), and although this
approach will be essential for dissecting how particular bacteria alter immune
responses, it will not replicate the complex changes that might be associated with
a naturally occurring dysbiosis. Our ability to generate a mouse with dysbiotic
skin microbiota overcomes this issue, and has allowed us to demonstrate that a
naturally acquired dysbiosis promotes increased inflammatory responses, and in
the case of cutaneous leishmaniasis increased disease. It is not clear how this
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transmission occurs, although consistent with our results, evidence from human
studies indicates that the environment influences the skin microbiota(Song et al.
2013), and L. major infections in mice may provide a model to study the
mechanisms involved.
The findings from our mouse model of cutaneous leishmaniasis are similar
to the dysbiosis that occurs during human cutaneous leishmaniasis. Interestingly,
the different topological sites of our samples did not show any differences in the
skin microbiota, although we only had a few samples from moist and sebaceous
sites. Yet comparable to what has been reported by culture dependent and
independent methods (Isaac-Marquez and Lezama-Davila 2003; Sadeghian et
al. 2011; Layegh et al. 2015; Salgado et al. 2016), our results demonstrated that
Staphylococcus aureus and Streptococcus spp. are highly abundant on lesional
skin. This dysbiosis was also present on skin sites adjacent to the lesion.
However unlike our mouse model, the dysbiotic skin microbiota did not appear to
be transmissible to contralateral skin sites. It is not yet clear why the dysbiosis is
confined to the lesional and adjacent skin sites in human cutaneous
leishmaniasis but it is likely to be due to differences in grooming and
environmental conditions between mice and humans. However, the similarities in
the dysbiotic microbiota between the mouse model and human cutaneous
leishmaniasis demonstrate the utility of our model system to study the role of skin
microbiota during leishmania infections.
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One of our findings was that skin dysbiosis does not cause immunologic
changes in the skin or disease by itself, nor did topical colonization with S.
xylosus, similar to results reported by recent studies (Naik et al. 2015). However,
in mice with a defective skin barrier induced by contact hypersensitivity to DNFB,
S. xylosus exacerbated the inflammatory response, assessed by increased
recruitment of neutrophils and upregulated expression of IL-1β. These results
are consistent with other studies showing that mice with barrier defects allow
Staphylococcus to penetrate the epidermal barrier and subsequently increase
cytokine expression in the skin (Nakatsuji et al. 2016). In some situations the
cytokine production may be protective, such as during a fungal infection(Naik et
al. 2015). However, in cutaneous leishmaniasis, neutrophils and IL-1β are
associated with increased pathology rather than the restriction of parasites
(Charmoy et al. 2016; Fernandez-Figueroa et al. 2012; Gimblet et al. 2015;
Gonzalez-Lombana et al. 2013; Novais et al. 2014a; Voronov et al. 2010). Thus,
we hypothesize that L. major infection disturbs skin barrier integrity while
simultaneously inducing a dysbiosis in the skin microbiota, which taken together
leads to the increased recruitment of neutrophils and IL-1β recruiting cells to the
skin, and causes increased lesion severity.
These results raise the obvious question of what role systemic or topical
antibiotics might play in moderating inflammatory responses associated with
leishmaniasis (Grice 2014). As previous studies with germ-free mice indicate that
commensal bacteria may contribute to lesion severity in cutaneous leishmaniasis
(de Oliveira et al. 1999; Naik et al. 2012; Oliveira et al. 2005), and our studies
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demonstrate that dysbiosis exacerbates disease, it is reasonable to predict that
antibiotic treatment might be beneficial in leishmaniaisis. While we have been
unsuccessful in moderating disease in mice by antibiotic treatment, there are
examples of antibiotic therapy being protective in some cutaneous leishmaniasis
patients (Aguiar et al. 2010; Ben Salah et al. 2013; Kim et al. 2009; Krolewiecki
et al. 2002). However, there are other studies that find no effect of antibiotic
treatment (Iraji and Sadeghinia 2005; Neva et al. 1997), and moreover when
such treatment shows a positive outcome the mechanism involved is not clear.
Given the different outcomes of studies looking at antibiotic treatment, and taken
together with our results, it appears that the role of antibiotics in treatment needs
further investigation.
In summary, our findings indicate that the skin microbiota not only
changes during leishmania infection, but when transmitted to naïve mice can
enhance disease to leishmania. These findings have obvious consequences
when considering how to limit disease severity in cutaneous leishmaniasis.
Moreover, since we find that the dominant bacteria associated with a leishmaniainduced dysbiosis differs depending upon the severity of disease in mice, further
epidemiologic studies with patients to determine the consequences of differing
types of dysbiosis are warranted. Finally, we found that dysbiotic skin microbiota
can be transmitted to conventional naïve mice, which provides a model to define
how and when dysbiosis might influence control of other infections, autoimmune
diseases and wound healing.
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CHAPTER 4: DISCUSSION
In this thesis we investigated whether IL-22 and the skin microbiota could
influence disease during cutaneous leishmaniasis. Our results have
demonstrated a role for IL-22 in limiting tissue damage, yet also demonstrates
that dysbiosis in the skin microbiota exacerbates inflammation during infection. In
both observations, expression of IL-1α and/or IL-1β, cytokines that drive
pathology during infection, were influenced by IL-22 and dysbiosis. Yet, changes
in IL-22 expression or the skin microbiota composition did not influence the
parasite burden, suggesting their roles in modulating disease during cutaneous
leishmaniasis are mediated by modulating the immune response to promote
wound healing or to exacerbate tissue damage. This chapter will discuss the
implications and challenges of regulating IL-22 and the skin microbiota as
therapies for cutaneous leishmaniasis; will discuss the utility of the dysbiotic
mouse model to study other inflammatory skin diseases; and will posit potential
ways the microbiota is changed during infection and how those changes may
drive the immune response to cause pathology in the skin.

4.1 Implications of a dose-dependent requirement for IL-22 and areas for
future investigation
Our data suggest a role for IL-22 in limiting pathology during cutaneous
leishmaniasis through initiating keratinocyte migration and decreasing the
release of pro-inflammatory cytokines that exacerbate inflammation and tissue
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damage. Yet, it was previously shown that IL-22 has no effect during a low dose
infection with L. major (Brosch et al. 2014). Similarly, this thesis demonstrated
that the protection provided by IL-22 was only observed with higher doses of the
parasite, suggesting that a certain threshold of infection-induced inflammation is
required for IL-22 to limit pathology. In fact, we observed that greater doses of
parasites induced higher expression of IL-22 in the skin (Figure 17a). In the
mouse model, higher doses of infection lead to the release of more inflammatory
cytokines and subsequently more tissue damage. It is not yet clear how parasite
burden dictates when IL-22 is required to limit protection or whether this dosedependence is also observed in human patients. Data from this thesis provides
the basis for future studies to investigate how this dose dependent requirement
for IL-22 is mediated.
Previous studies speculated that IL-22 could have protective effects during
leishmaniasis due to correlative studies in human patients (Pitta et al. 2009;
Ghosh et al. 2013). However, these studies did not demonstrate a mechanism of
how that protection is mediated. In this thesis, we demonstrated that in the
absence of IL-22, mice infected with L. major had increased lesion sizes and
lesion pathology. While the exact mechanism still needs further investigation, we
observed aberrant expression of genes that regulate keratinocyte migration,
keratin 6 and keratin 16, in the absence of IL-22. As keratinocyte mobility is
required for wound healing (Haase et al. 2003), we hypothesize that this defect in
keratinocyte mobility could delay lesion resolution during cutaneous
leishmaniasis (Figure 17b). Surprisingly, we did not observe a difference in
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keratinocyte proliferation or survival during infection with L. major in the absence
of IL-22. But these observations were made using an intermediate dose of
infection. Because our data demonstrates a dose-dependent requirement for IL22, future studies could examine keratinocyte proliferation and survival during
infection with varying doses of L. major. Due to increased inflammation with a
high dose of infection, it is likely that more keratinocyte death is observed and the
pro-survival effects of IL-22 become more apparent. These studies would provide
more insight into how IL-22, parasite burden, and keratinocyte function contribute
to disease resolution during cutaneous leishmaniasis.
Keratinocytes release IL-1α in response to injury or irritation in the skin
(Kondo and Ohshima 1996; Spiekstra et al. 2005), which increases inflammatory
cell recruitment into the skin. Simultaneously, the damaged keratinocytes could
signal to innate cells to release damage-associated molecules like IL-1β. In the
absence of IL-22, we observed increased expression of both IL-1α and IL-1β
during L. major infection (Figure 17c). IL-1β, in particular, is associated with
neutrophil recruitment into the skin and increased pathology during cutaneous
leishmaniasis (Fernandez-Figueroa et al. 2012; Novais et al. 2014a; Voronov et
al. 2010; Gonzalez-Lombana et al. 2013; Charmoy et al. 2016). Excessive
neutrophil recruitment and IL-1β release could also delay wound healing in the
skin (Gutierrez-Fernandez et al. 2007; Goren et al. 2003; Mirza et al. 2013).
Future studies could block IL-1 signaling and neutrophil recruitment in the
absence of IL-22. These studies could determine if limiting this type of
inflammation is another mechanism IL-22 uses to aid in tissue resolution,
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Previous studies on IL-22 and leishmaniasis did not provide a clear
understanding of the role of IL-22 during leishmania infections. Data from this
thesis demonstrated that IL-22 limits tissue damage and aids lesion resolution
during cutaneous leishmaniasis in a parasite dose-dependent manner. Future
studies will provide more details on how parasite dose, inflammation, tissue
damage, and IL-22 interact during infection with leishmania. With this
information, we could better understand how to use IL-22 in the treatment of
cutaneous leishmaniasis.

4.2 Leishmania in the field of the skin microbiota
In the field of the skin microbiota, some studies are only able to
characterize how the microbiota changes throughout disease. In this thesis, we
aimed to determine whether the microbiota changes during infection as well as
understand what those changes could mean. We demonstrated that leishmania
infection, in mice and humans, induces changes in the skin microbiota dependent
upon the severity of the disease. This dysbiosis was characterized by high levels
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Figure 17: The role of IL-22 during L. major infection. (a) IL-22 is induced during L. major
infection in a dose dependent manner. (b) This production of IL-22 inhibits the expression of antimigratory factors, keratin 6 and keratin 16, in keratinocytes. This blockade allows keratinocyte
mobility and ultimately leads to wound closure and lesion resolution. (c) In the absence of IL-22,
L. major lesions are larger and more severely ulcerated. This damage to the epithelial barrier
could lead to the release of IL-1α from damaged keratinocytes as well as signal to innate cells to
produce IL-1β in response to DAMPs. Additionally, the open wound could become exposed to
bacterial products, which would also prompt the release of IL-1β.

of Staphylococcus spp. or Streptococcus spp. in the community of bacteria
present on the skin. These genera of bacteria, in particular Staphylococcus spp.,
have been associated with several skin disorders including atopic dermatitis,
psoriasis, and chronic diabetic wounds (Gao et al. 2008; Alekseyenko et al.
2013; Kong et al. 2012; Price et al. 2009; Grice et al. 2010; Loesche et al. 2016;
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Gardner et al. 2013). But the conclusions we can draw about these associations
are limited due to the nature of some of the studies. Work presented in this thesis
described that dysbiosis induced by leishmania infection does not induce
inflammation on naïve skin, but after inflammation is initiated, either by L. major
infection or contact hypersensitivity, the dysbiotic skin microbiota exacerbated
inflammation and subsequent tissue damage. These data tell us that the skin
microbiota is not only an effect of inflammation in the skin, but also plays an
active role in disease.
Mono-colonization with a particular bacterium of interest has been used in
several studies to determine if those bacteria play a role in disease. S.
epidermidis, in particular, has been used to demonstrate that commensals can
drive cytokine production from CD8+ T cells to protect against C. albicans
infection (Naik et al. 2015). Additionally, mono-colonization with S. epidermidis
primes regulatory T cells early after birth to limit inflammation during challenge
with the bacterium later in life (Scharschmidt et al. 2015). These studies suggest
that this common skin commensal is highly active in skin immunity. Similar
observations were made during leishmania infection. Using a germ-free mouse
model of cutaneous leishmaniasis, previous studies demonstrated that S.
epidermidis drives inflammation and lesion development during L. major infection
(Naik et al. 2012). These studies provided useful information about how a
common skin commensal like S. epidermidis could influence the outcome of
cutaneous leishmaniasis. However, there were limitations to these observations.
We observed that during infection with leishmania parasites, S. xylosus and S.
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aureus were dominant on the lesions of mice and humans, respectively. Our data
suggests that S. epidermidis may be irrelevant during infection with leishmania.
While mono-colonization can teach us about how the immune response interacts
with common skin commensals, we believe it is important to study the
commensals that are affected by inflammation in order to investigate how those
changes influence disease. Utilizing the bacteria that naturally dominate during
an inflammatory state might provide a better idea of interactions between the skin
microbiota and the immune response during disease.
Recent studies demonstrated that in a mouse model of atopic dermatitis,
S. aureus increased with disease, but also was important in driving inflammation
(Kobayashi et al. 2015). Similarly, another study showed that a breakdown of
skin integrity allowed S. aureus to translocate deeper into the skin and
exacerbate inflammation (Nakatsuji et al. 2016). We believe these types of
studies, as well as work presented in this thesis, go beyond characterizing the
changes in the skin microbiota and begin to ask how those changes influence
disease, potentially moving the field forward.

4.3 Utility of the dysbiotic mouse model to study other inflammatory skin
disorders
Many studies have demonstrated associations with disease in the skin
and a dysbiosis in the skin microbiota. Currently, our investigations into the skin
microbiota are focused on determining if dysbiosis causes inflammation in other
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inflammatory skin diseases. Some investigators, as well as our lab, have used
mono-colonization of a particular bacterium to examine the effect of dysbiosis on
disease and inflammation. However, there are limitations to this method. It
typically requires a large amount of bacteria and multiple applications for a
transient colonization. We established a model in these studies that could
address some of these limitations. Uninfected mice co-housed with L. major
infected mice acquired a similar dysbiosis characterized by a dominance of S.
xylosus. While transferring dysbiosis by co-housing in other studies also transfers
disease (Elinav et al. 2011b; Zenewicz et al. 2013)our model transferred the
dysbiosis without inflammation in the skin, separating dysbiosis from disease.
This system allowed us to investigate the role of dysbiosis prior to infection or
disease. We believe this system could be useful in the study of other
inflammatory skin diseases.
Our co-housing model of dysbiosis could allow us to test whether
dysbiosis prior to injury exacerbates pathology in mouse models of psoriasis,
atopic dermatitis, chronic diabetic wounds, or any other model of inflammatory
skin disease. In our system, we used L. major infected mice to create dysbiosis
on the skin of co-housed naïve mice. However, other inflammatory skin diseases
could potentially be used to establish this goal. It is not yet known whether the
dysbiosis caused in other inflammatory skin models is transferrable by cohousing. But some models induce similar, if not greater, inflammation than
leishmania infection and thus could potentially use a co-housing system to test
the importance of dysbiosis during infection. It would be interesting to determine
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if other dysbiosis-causing commensals influence disease as S. xylosus does
during infection with L. major. These studies could provide insight into which
members of the microbiota are important in various skin diseases.

4.4 Understanding how changes in the skin microbiota influence the
immune response
Our data demonstrates that leishmania infection causes changes in the
skin microbiota and that acquiring a dysbiotic skin microbiota prior to infection
magnifies inflammation and subsequent pathology in the skin. While these
studies indicate that the skin microbiota plays a role in disease, it is not yet clear
how these interactions are mediated.
We hypothesize that inflammation induced by infection initiates the
changes in the microbiota that go on to increase immunopathology. Infection with
leishmania parasites drives immune cell infiltrate into the skin, cytokine and
chemokine production that magnifies that infiltration, and the production of
antimicrobial molecules (Figure 18a). Molecules like reactive oxygen species
(ROS) and nitric oxide (NO) are important in parasite control, but can also have
anti-bacterial properties. Innate cells produce these molecules during infection
with leishmania parasites, but this production mostly happens in the dermis of the
skin, potentially not close enough to affect the bacteria on the surface.
Keratinocytes, on the other hand, are in the epidermis with direct access to
surface bacteria. ROS and NO in the skin can be upregulated in keratinocytes in
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response to cytokines like IFN-γ (Bito and Nishigori 2012; Sur et al. 2002). While
one study suggests that keratinocytes can produce NO during leishmania
infection (Blank et al. 1996), it is unclear if this production plays any role in the
change in the skin microbiota. The same is true for antimicrobial peptides
(AMPs). During L. major infection, the expression of some AMPs was increased,
while others decreased in expression in the skin (data not shown). There is
evidence that lesions are more severe in the absence of the antimicrobial
peptide, cathelicidin (Kulkarni et al. 2011), but whether the skin microbiota plays
a role in this phenotype is unknown. Analyzing how the skin microbiota changes
during infection in cathelicidin deficient mice as well as in other AMP deficient
mice could inform us about the importance of these molecules in cutaneous
leishmaniasis and the skin microbiota.
Our studies utilized the 16S ribosomal RNA gene to characterize how the
skin microbiota changed throughout infection with leishmania. While this method
was useful to identify the community of bacteria on the skin throughout infection,
having more detailed information about how those bacteria change would be
useful to better understand how the microbiota interacts with the host immune
response. Our data describes the changes in the skin microbiota at the genus
and species level, but it is clear that there are strain level differences in the skin
bacterial communities that could stimulate the immune response differently (FitzGibbon et al. 2013; Oh et al. 2014; Oh et al. 2016). For example, while some
strains of S. aureus stimulated IL-17 production from γδ T cells through IL-1β
signaling, other strains were unable to produce this reaction (Maher et al. 2013).
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As IL-17 and IL-1β are known to drive pathology during cutaneous leishmaniasis,
understanding strain differences could be important. We observed that S. xylosus
and S. aureus was dominant on the lesions of leishmania infected mice and
humans, respectively. However, these bacteria were also present on naïve and
uninfected skin. We do not know if there are strain differences of bacteria on the
skin before and after infection, but strain differences could influence bacterial
gene expression and the type of host immune response initiated. Studies
investigating how strains of bacteria change throughout disease could help us
better understand dysbiosis and how it influences inflammation.
The bacteria that are a part of our microbiota also produce proteins and
metabolites that can stimulate different immune responses. Short chain fatty
acids (SCFAs) like butyrate, acetate, and propionate, have been shown to induce
regulatory T cells, activate the inflammasome and IL-18 production, and regulate
macrophage function (Smith et al. 2013; Macia et al. 2015; Chang et al. 2014).
Indole, a tryptophan catabolite from microbiota, can engage the aryl hydrocarbon
receptor (AHR) to induce IL-22 expression (Zelante et al. 2013).
Most studies have focused on intestinal metabolites and their interactions
with the immune response. The bacterial metabolites of the skin have been less
studied. However, recent studies have used 3D mass spectrometry mapping
along with 16S rRNA gene sequencing to characterize the metabolites of the skin
microbiota (Bouslimani et al. 2015). These studies demonstrate that members of
the skin microbiota produce metabolites differently. During dysbiosis in
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cutaneous leishmaniasis, it is likely that different metabolites are produced when
certain bacteria become dominant. These metabolites could also be different
between strains of bacteria that are present before and after infection. Recent
studies have determined that there are strain-level differences in the production
of metabolites from Propianibacterium acnes, a common skin commensal
implicated as a pathogen of acne vulgaris. These studies suggest that different
strains of P. acnes from healthy and diseased skin produce different levels of the
metabolite, porphyrin, which may play a role in the pathogenesis of the disease
(Johnson et al. 2016). Changes in the skin microbiota caused by leishmania
infection may introduce different metabolites from the dominant bacteria that
drive inflammation and subsequent pathology during cutaneous leishmaniasis
(Figure 18b). Studies that examine the skin microbiota and their metabolites on
healthy skin and how they change during disease are informative. But
understanding the different roles metabolites play in modulating disease would
be more beneficial. Future studies should examine how metabolites change
during disease but also examine the interactions between bacterial metabolites
and the immune system. In cutaneous leishmaniasis, where the pathology is
largely mediated by the immune response, understanding the role of metabolites
could be useful when considering how to regulate immunopathology.
Ultimately, future research on immune mediated diseases like cutaneous
leishmaniasis should involve studying the immune response in addition to
applying information from the genomics, transcriptomics, and metabolomics
study of the microbiota. This type of research could build upon the work done in
100

this thesis and would provide a more complete picture of how the microbiota
interacts with the immune system in disease.

4.5 Antibiotics and cutaneous leishmaniasis
As our results have demonstrated that the skin commensal, S. xylosus, can
exacerbate pathology in the skin during cutaneous leishmaniasis, using
antibiotics in combination with anti-leishmania drugs might be a useful therapy.
There are several studies examining the effects of different antibiotics on
cutaneous leishmaniasis, but the most studied has been Paromomycin.
Paromomycin is a protein synthase inhibitor that has been shown to increase
lesion resolution during cutaneous leishmaniasis (el-Safi et al. 1990; Asilian et al.
1995; Ben Salah et al. 1995; Iraji and Sadeghinia 2005; Asilian and Davami
2006; Aguiar et al. 2010; Ben Salah et al. 2013). However just as many studies
have demonstrated that paromomycin treatment has no effect or is less effective
than current pentavalent antimony treatments (Hepburn, Tidman, Hunter 1994;
Neva et al. 1997; Soto et al. 1998; Faghihi and Tavakoli-kia 2003; Armijos et al.
2004; Shazad, Abbaszadeh, Khamesipour 2005). These studies are complicated
to interpret due to small study sizes, different species of the parasite as well as
different methods of pentavalent antimony and antibiotic application (Kim et al.
2009). A well-controlled analysis is required to understand the most effective
method to administer Paromomycin and if this treatment should be given in
combination with drugs that also target the parasite.
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Other antibiotics, like azithromycin, have also been reported to decrease
lesion size and parasite burdens during cutaneous leishmaniasis (Krolewiecki et
al. 2002), but more studies are needed to better understand how this protection

a

b Dysbiosis

AMPs
IFN-γ
TNF-α
IL-17
IL-22
CD4

CD4

CD8

Exacerbates
inflammation

IL-1α
IL-1β

IL-17
IFN-γ

CD8

Tissue damage
Figure 18: The skin microbiota, dysbiosis, and leishmania infection. (a) Infection with
leishmania parasites causes an infiltration of immune cells into the skin that produce inflammatory
cytokines. These cytokines can stimulate keratinocytes to produce ROS, NO, and AMPs in the
epidermis. (b) The production of these antimicrobial factors initiates changes in the skin
microbiota, which leads to a dominance of a particular bacterium. These bacteria can release
metabolites and/or virulence factors, which modulate the immune response to exacerbate
pathology.
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is achieved. Even antifungals have been used to help lesions heal faster and
decrease parasite burdens during cutaneous leishmaniasis (Pinheiro et al. 2016).
Amphoterin B is classified as an anti-fungal and anti-protozoan drug and
has been effective as a topical treatment during cutaneous leishmaniasis (Ruiz et
al. 2014). These antibiotics are believed to help during the resolution of
leishmania infections by reducing parasite burdens. The mechanism of parasite
control is not understood with the use of any of these antibiotics. Azithromycin
can modulate macrophage function and can induce cytokine production from
these cells (Krolewiecki et al. 2002; Xu et al. 1996; Ianaro et al. 2000). Thus, it
can mediate anti-parasitic immunity by direct interactions with the immune
response. Another possibility is that antibiotics modulate the skin microbiota,
which indirectly shapes the type of immune response initiated during infection.
Interestingly, there is evidence that Paromomycin can decrease bacterial
contamination of leishmania lesions as well as decrease parasite burdens (el-On,
Sneier, Elias 1992). It is possible that other antibiotics could also influence the
bacteria on lesions during cutaneous leishmaniasis, but further characterization
of the microbiota of leishmanial lesions after antibiotic treatment is needed to
determine the effects of these drugs.
In agreement with work presented in this thesis, other studies have
demonstrated that Staphylococcus spp. and Streptococcus spp. are significantly
increased during cutaneous leishmaniasis (Layegh et al. 2015; Salgado et al.
2016). We hypothesize that utilizing antibiotics with some specificity for these two
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genera might help alleviate disease. Current antibiotics tend to have a broad
spectrum of targets and may not be ideal to target specific bacteria. Information
from the species and strain levels of these bacteria may be required to generate
antibiotics effective to treat cutaneous leishmaniasis. If such antibiotics are
produced, a combined therapy of anti-leishmania and anti-staphylococcal or antistreptococcal could be the most effective way to clear the parasite and regulate
immune mediated pathology.
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